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Porcine epidemic diarrhea (PED) virus causes effusive diarrhea in pigs of all ages and 
high mortality among pre-weaning pigs. The PED virus (PEDV) is one of several important 
swine pathogens which cause significant economic losses to the swine industry. The first 
outbreak of PED in the United States occurred in 2013. Since then, various studies have been 
conducted to characterize the virus and its pathogenesis/pathogenicity and to develop diagnostic 
testing and reagents for the virus. The goals of the following three experiments in this 
dissertation were to characterize protective host antibody response against the PEDV, elucidate 
mechanisms responsible for the long duration of viral fecal shedding, and identify the putative 
receptor-binding domain of the virus. 
The first study characterized clinical and antibody responses of pigs following 
experimental PEDV infection/re-infection. After experimental inoculation, naive 3-week-old 
pigs developed diarrhea starting 2 days post infection (dpi). While most of the pigs recovered by 
10 dpi, the virus continued to shed in feces from all pigs until 14 dpi and in some pigs up to 35 
dpi. The pigs developed virus-specific antibodies of all major isotypes as early as 7-10 dpi, and 
serum virus neutralizing (VN) antibody was detectable in the majority of pigs (92%) by 14 dpi, 
suggesting that antibody appearance, particularly VN antibody, may coincide with the progress 
toward recovery. While all structural proteins of PEDV except envelope protein were found to be 
immunogenic, the appearance of antibody against spike (S) protein seemed to be associated with 
the development of neutralizing activity in blood circulation. When the pigs were re-exposed to 
the same strain of PEDV (i.e., homologous challenge) almost 2 months after the initial infection, 
neither clinical signs of diarrhea and other abnormalities nor viremia were observed in the pigs. 
Fecal shedding of the virus, however, occurred for 14 dpi even though those pigs had detectable 
v 
 
antibodies in serum and oral fluid at the time of re-exposure, suggesting that prior infection can 
provide clinical protection against a homologous virus challenge but not sterile immunity. As 
antibody profiling of oral fluids demonstrated that a relatively high level of IgA was maintained 
until re-inoculated whereas IgG in both sera and oral fluids continued to decline after 21-28 dpi, 
mucosal IgA may be responsible for clinical protection from the subsequent inoculation. 
The second study was conducted to evaluate if the presence of PEDV in non-intestinal 
tissue(s) contributes to prolonged fecal shedding of the virus following infection. Blood and 
various organs collected from pigs after experimental inoculation of PEDV were examined by a 
real-time RT-PCR and/or tissue assays such as immunohistochemistry and fluorescent in situ 
hybridization for viral RNA or antigen. Viremia observed in the challenged pigs starting on dpi 1 
and then disappeared after 7 dpi. PEDV RNA was also detected in various tissues besides the 
small intestine as early as 1 dpi, which coincided with viremia, but was no longer detectable after 
14 dpi except in the small intestine and mesenteric lymph node (MLN) in which viral RNA 
continued to be detected at 28 dpi. The virus could be isolated from MLN until 14 dpi. The 
findings from the study did not support the contribution of non-intestinal tissues to fecal 
shedding for the extended period (35 dpi). Longer duration of fecal shedding of PEDV may be 
attributed to viral replication in the small intestine while viremia may contribute to wide tissue 
distribution of the virus. 
In the third study, a putative receptor-binding domain (RBD) of PEDV was identified in 
the S1 region of the S protein via bioinformatics, comparative structural biology, and homology 
modeling for protein structure in comparison to alphacoronaviruses with known RBD sequence. 
A recombinant protein produced from that gene fragment was recognized by anti-PEDV swine 
sera from pigs experimentally inoculated with the virus, indicating the recombinant RBD protein 
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maintained its native form as it was in the virus. Rabbit polyclonal and rat monoclonal antibodies 
that were generated against the putative RBD protein were able to neutralize PEDV infection in 
Vero cells, which are permissive to PEDV. These findings suggest the presence of neutralizing 
epitope(s) in the putative RBD protein and its potential utility as a vaccine antigen or antigenic 
basis for serodiagnosis. Furthermore, the protein bound to the surface of Vero cell, suggesting 
that the putative RBD identified in the study should be a receptor-binding domain of PEDV. 
Since Vero cells do not possess aminopeptidase N (APN) which is a known cellular receptor for 
alphacoronaviruses, PEDV may bind to a cellular receptor other than APN.  
Overall, the present research contributes to the understanding the ontogeny of antibody 
response to PEDV and protective immunity to a subsequent infection, the pathogenesis of PEDV 
in weaned pigs, and virus attachment to permissive cells at the cellular level, leading to better 





CHAPTER 1. GENERAL INTRODUCTION 
 
1.1 Dissertation organization 
This dissertation is composed of an abstract, followed by a general introduction, three 
research papers, a general conclusion, and an acknowledgment. Chapter 1 is the literature review 
that provides an overview of the current knowledge of PEDV immune response and host-
pathogen interaction. Chapters 2, 3 and 4 are research papers, which have been prepared to be 
submitted to the Clinical and Vaccine Immunology, Veterinary Microbiology, and the Journal of 
Virology, respectively. References, tables, and figures of each research paper follow the 
discussion section of their corresponding paper. The last chapter contains the general conclusions 
of the studies. 
 
1.2 Literature review 
 
1.2.1 Introduction 
Porcine epidemic diarrhea (PED) is an important enteric disease of swine. The disease 
has resulted in significant economic losses to multiple swine producing countries worldwide (1-
4). The disease was first reported in European and then Asian swine industries over the last 30 
years. The virus, later named PED virus (PEDV), was first identified in the UK in 1971 (1) then 
in Belgium in 1977 (2, 3, 5). Despite having a notorious record in pork-producing countries (6), 
PEDV was not well recognized worldwide (3). In April of 2013, PEDV suddenly appeared in US 
swine and rapidly spread across the country. The virus killed about 10%, or 5-8 million, of the 
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US swine population in the first year of its outbreak, creating a major economic blow ($900 
million-1.8 billion/year revenue loss) to the US swine industry (3, 7).  
Clinical and epidemiological characteristics of PEDV infection are similar to those of 
transmissible gastroenteritis virus (TGEV) infection. Although both PEDV and TGEV are in the 
same genus, these two viruses are genetically and antigenically distinct from one another, 
requiring differential diagnostic tests (3, 8, 9). In the early 1970s, the first reporting of PED 
clinical signs and symptoms were similar to the symptoms of TGEV infection, but neonatal 
piglets were lesser affected than recent PED outbreaks (1, 9, 10). PEDV is transmitted fecal-
orally, causes acute watery diarrhea, dehydration, and high mortality particularly in neonatal 
piglets. It replicates in the mature intestinal enterocytes, which leads to villous atrophy and 
enteritis thereby causing malabsorptive watery diarrhea with anorexia and occasional vomiting in 
pigs of all ages (11-15). To understand the immune response and to achieve effective and 
protective immunity and better control of PED, much deeper understanding of PEDV, 
particularly characterization of the immune response, receptor binding, and host-pathogen 
interaction, is necessary. Therefore, this review will focus on the immune response against 
PEDV, the role of each viral protein in infection and immunity, and viral receptor binding.  
1.2.2 Classification and taxonomy 
According to the International Committee on Taxonomy of Viruses (ICTV) published on 
July 2018, PEDV is grouped into the realm Riboviria, order Nidovirales, suborder 
Cornidovirineae, family Coronaviridae, subfamily Orthocoronavirinae, genus 
Alphacoronavirus, subgenus Pedacovirus (16). According to the new classification, the order 
Nidovirales comprises seven suborders: Abnidovirineae, Arnidovirineae, Cornidovirineae, 
Mesnidovirineae, Monidovirineae, Ronidovirineae, and Tornidovirineae. They are grouped 
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together due to their similarity in general morphology, genome organization, and gene 
expression and transcription strategy.  
The family Coronaviridae is the largest group in the order Nidovirales. The family 
Coronaviridae comprises two subfamilies: Letovirinae and Orthocoronavirinae. The subfamily 
Orthocoronavirinae includes four genera: Alphacoronavirus, 
Betacoronavirus, Gammacoronavirus, and Deltacoronavirus (9, 16, 17). The genus 
Alphacoronavirus comprises 12 different subgenera. The subgenus Pedacovirus consists of 
PEDV and Scotophilus bat coronavirus 512. The subgenus Tegacovirus under genus 
Alphacoronavirus comprises two other important swine pathogens besides PEDV: TGEV 
identified in 1946 and porcine respiratory coronaviruses (PRCV) identified in 1984 (9, 16).   
Other coronaviruses (CoVs) commonly found in swine are porcine hemagglutinating 
encephalomyelitis virus (PHEV), identified in 1962 and belonging to the genus Betacoronavirus, 
and porcine deltacoronavirus (PDCoV), identified in 2012 and belonging to the genus 
Deltacoronavirus. Swine enteric coronavirus (SeCoV) was identified in Italy in 2016 and 
emerged as a recombinant of the S gene of PEDV CV777 and TGEV (18). While the majority of 
swine coronaviruses (PEDV, TGEV, PDCoV) cause enteric disease, PRCV that is the S gene 
deletion mutant of TGEV, has the tissue tropism for respiratory tract and causes mild respiratory 
disease in young pigs as part of the porcine respiratory disease complex (9). 
1.2.3 Virion and genome 
PEDV is an enveloped virion containing the single-stranded positive-sense RNA genome, 
and its size is about 95-190 nm in diameter, including corona-like projections from the surface 
which are 18-23 nm in length (2, 6, 19). It contains a centrally located electron-opaque body. The 
4 
 
PEDV genome is approximately 28kb with a 5’ cap and 3’ polyadenylated tail, contains a 5’ 
untranslated region (UTR) and comprises seven overlapping open reading frames (ORFs) (9, 20). 
The genomic organization of PEDV is arranged as 5’-UTR-ORF1a-ORF1b-S-ORF3-E-M-N-
UTR-3’ (8, 21). The seven ORFs encodes the replicase (ORF1a and ORF1b), the accessory 
protein ORF3, and structural proteins designated as spike (S), envelope (E), membrane (M), and 
nucleocapsid (N).  
The replicase gene (ORF1a and ORF1b) occupies about two-thirds of the total genome 
and encodes nonstructural proteins (nsps), including RNA-dependent RNA polymerase, which 
are necessary for virus replication. The ORF1a translation results in polyprotein pp1a. The 
ORF1b is generated by a negative ribosomal frameshifting and results in extending pp1a into 
pp1ab. These pp1a and 1b are further cleaved by internal proteases, resulting in 16 nsps (9, 20, 
21). Among major structural proteins, S protein comprises a distinct surface protein, which is 
involved in attachment and entry of the virus. E and M proteins are in the envelope of the virus 
and are involved in virus assembly and providing structure. N protein is associated with viral 
RNA inside the virion and provides the structural basis for the virion (16).  
PEDV shows a buoyant density of 1.18 on sucrose. The virus is sensitive to ether and 
chloroform and is stable at 4-50 °C (22). The virus in a liquid phase is inactivated when heated to 
more than 60 oC for 30 minutes. In the presence of organic matter (e.g., feces), PEDV on the 
surface of an aluminum tray can be inactivated by holding it at 71 °C for 10 minutes or at 20 °C 
for 7 days (23). The virus is stable in the pH range of 4-9 and is inactivated by various acidic and 
alkaline disinfectants (22, 24).  
The genomic organization and phylogenetic analysis showed that PEDV strains are more 
closely related to bat alphacoronaviruses than to other members of the Alphacoronavirus genus. 
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This suggests PEDV and bat coronavirus may have a common evolutionary ancestor, and cross-
species transmission between bats and pigs might have occurred (11, 25). Genetic and 
phylogenetic analyses of global PEDV have been performed based on full-length genomic RNA 
and individual genes (S, S1, S2, E, M, N, ORF3). Among them, analyses based on full-length S 
or S1 gene for genetic diversity closely resembles the whole genome analysis, which suggests 
their usefulness of S or S1 gene for analyzing the genetic diversity and relatedness of global 
PEDV (6, 26). 
Based on phylogenetic analysis of the whole genome, PEDV strains can be classified into 
two distinct groups as genogroup 1 (G1) or classical and genogroup 2 (G2) or emerging (11, 26, 
27). Each group is further subdivided into various clusters (i.e., subgroups). Subgrouping varies 
depending on the full-length genome or full-length S gene. Various research groups have divided 
the subgroups into different clusters based on the origin or the clades, resulting in the 
inconsistency issue (26, 28). It could be due to the complex evolution of PEDV strains, which is 
common among RNA viruses (16). G1 encompasses the CV777 strain and other similar strains 
including strains LZC, DR13 and SM98. G2 contains emerging Asian clade, North American 
(NA) clade and S-INDEL clade. 
1.2.4 Nonstructural proteins (nsps) 
1.2.4.1  Nonstructural protein 1 (nsp1) 
Coronavirus nsp1 is the most N-terminal nsp among replicase polyproteins and encoded 
by alpha and beta coronaviruses (16). Nsp1 is the cleavage product of polyprotein pp1a and 
processed by papain-like proteinase 1 activity of nsp3 (29). Nsp1 of PEDV is comprised of 110 
amino acids (30). The majority of coronavirus nsp1s are a potent interferon (IFN) antagonist. As 
such, a mutation in nsp1 could lead to the attenuation of viral pathogenicity which could be a 
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strategy to generate modified live vaccine candidates (31, 32). An overexpression study has 
shown that TGEV nsp1 suppresses reporter protein translation similar to other coronaviruses 
(32). Similarly, overexpression of PEDV nsp1 also leads to suppression of type I IFN response 
by degrading the CREB-binding protein (CBP) in the nucleus and suppressing IFN stimulated 
gene (ISG) (30, 33).  
1.2.4.2 Nonstructural protein 3 (nsp3) 
Nsp3 is one of the several nonstructural proteins that suppress IFN production and is 
conserved among coronaviruses (33). It is a large transmembrane protein that includes different 
functional domains and proteinase activity. The different domains are the acidic domain (Ac), 
papain-like protease 1 and 2 (PLP1 and PLP2), ubiquitin-like domains, and ADP-ribose-
phosphate (ADRP) domain (34, 35). Both PLP and deubiquitinase activities have been reported 
for PEDV and TGEV nsp3 proteins whereas ADRP activity has been reported only for TGEV 
nsp3 proteins (36). Activities of these domains have reportedly been associated with coronavirus 
pathogenicity (37, 38). Papain-like proteases (PLP1 and PLP2) and nsp5 cleave the polyproteins 
into individual non-structural proteins. Overexpression of PEDV PLP2 has been shown to 
deubiquitinate cellular innate viral nucleic acid sensors (RIG-I and STING), leading to lower 
IFN production (35). Similarly, live attenuated PED vaccine viruses derived from the DR13 or 
CV777 strains have been shown to contain several point mutations along with eight amino acid 
deletions in nsp3 protein (39). This evidence clearly suggests the important role of nsp3 protein 
in the pathogenicity of PEDV and its potential utility in gene manipulation to generate attenuated 




1.2.4.3 Nonstructural protein 5 (nsp5) 
Nsp5 is also known as 3C-like protease (3CLpro). It encodes the main CoV proteinase 
(Mpro) which is involved in 11 cleavages of pp1a/pp1ab not performed by nsp3 (16, 29). 
Overexpression of PEDV nsp5 has been shown to cleave NF-κB essential modulator (NEMO), 
thereby antagonizing IFN production (40). In addition, a recent study has reported that 
overexpression of PDCoV nsp5 also antagonizes IFN signaling through cleavage of STAT2 (41). 
Additional studies are required to elucidate the role of nsp5 in the pathogenesis and virulence of 
PEDV during infection in animals.  
1.2.4.4 Nonstructural protein 14 (nsp14) 
Nsp14 contains 3’-5’ exonuclease (ExoN) and 7-methyltransferase (N7-MTase) activities 
(29, 42). This protein has a critical function as a ribonuclease and plays an important role in the 
proofreading of viral RNA during replication and synthesis (43). Overexpression of PEDV nsp14 
has been shown to antagonize IFN generation, highlighting its role in innate immunity (33). 
TGEV nsp14 has also demonstrated a similar effect recently (44). In the same study (44), 
researchers showed that a TGEV virus mutant in the first zinc-finger motif in ExoN area of 
nsp14 caused reduced dsRNA and, as a result, less IFN production.  
1.2.5 Other nonstructural proteins  
Nsp7 and nsp8 together form a hexadecameric complex with a central pore which may 
wrap double-stranded RNA to help in viral RNA synthesis (45). Nsp9 is shown to bind single-
stranded RNA as an RNA-binding protein (RBP) (46). Nsp10 comprises the Zinc-binding 
domain and might play a role in the processing of nsp5 and functions as co-factor of nsp16 (16, 
47). Interactions among nsp10, nsp14, and nsp16 are involved in the generation of the mRNA 5’ 
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cap and are crucial for viral replication fidelity (16, 48). No information on nsp 2, 4, 6, 11, 12 
and 13 are available. 
1.2.6 ORF3 protein 
PEDV ORF3 is an accessory protein, encoded by subgenomic mRNA, located between S 
and E gene (49). It is about 224 amino acids in length and shows high homology across 
alphacoronaviruses including TGEV, bat coronavirus, and human coronaviruses HCoV-229E 
and HCoV-NL63. (50, 51). The ORF3 protein in human CoVs is a transmembrane protein with 
ion channel activity incorporated in the viral envelope and is involved in morphogenesis (39, 52-
54). Likewise, PEDV ORF3 has also been reported to encode an ion channel protein and 
regulates virus production (54). Virus production could increase in the presence of ORF3 
although it is not essential for viral replication in cell culture (55).  
It has been reported that cell-adapted strains of human CoVs and PEDV tend to have 
some modifications in ORF3 as compared to their parental strains (39). PEDV DR13 strain 
obtained after 100 passages in cell culture resulted in truncated ORF3 (56). Some reports have 
shown that long serially passaged virus with truncated ORF3 exhibited reduced pathogenicity in 
neonatal pigs (57-59). However, such an observation is not universally applicable to all ORF3 
truncations. Mutation and truncation of ORF3 may be more associated with cell adaptability than 
with attenuation. Intact ORF3 might negatively affect virus growth in cell culture (60, 61). It has 
been demonstrated that sequence variations of ORF3 affect PEDV replication, and truncation or 
single point mutation helps to increase the adaptability (59). The study identified amino acids 
responsible for impairing the rescue of PEDV from reverse genetics in vitro and showed that 
mutation of two of those key amino acids ameliorated the virus rescue (62). Another group, on 
the other hand, was able to rescue PEDV from reverse genetics with an intact ORF3 gene, and 
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any disruption introduced to the gene did not increase virus titer in cell culture, suggesting strain 
variation (63). More studies are required to have a definitive understanding of the role of ORF3 
in virus adaptation and pathogenicity. 
1.2.7 PEDV structural proteins 
Among seven ORFs, four comprise the last one-third of the genome and encode for major 
structural proteins (21). Major structural proteins are spike (S, 180–220 kDa), membrane (M, 
27–32 kDa), nucleocapsid (N, 58 kDa) and envelope (E, 7 kDa) (16). Three of the structural 
proteins (S, M, and E) are located in the viral envelope, and N protein is associated with the viral 
genome inside the virion (16, 19). Further details are described below. 
1.2.7.1 Spike protein 
The surface of PEDV and other coronaviruses is comprised of the trimers of S protein 
(16). Like other CoV S proteins, PEDV S protein is a class I viral glycoprotein which forms 
trimer peplomers on the virion surface (21, 64). It is responsible for receptor binding and fusion 
of host cell receptors and plays a critical role in early steps of infection (16). The S protein 
monomers form a club-shaped trimer structure and make a long projection on the virion surface, 
giving its typical crown-like appearance on electron micrograph (2). Similar to other CoV S 
proteins, the PEDV S protein monomer is made of an N-terminal signal peptide, a large 
extracellular region, a single transmembrane domain, and a short cytoplasmic tail (65). The 
protein enters into the endoplasmic reticulum via a signal peptide, and it acquires N-linked 
glycosylation (66).  
In many coronaviruses, the S protein is cleaved into S1 and S2 fragments by cellular 
proteases or trypsin (16, 67). PEDV S protein is roughly about 1386 residues long and can be 
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functionally divided into S1 (1-729) and S2 (730-1386) domains with distinct functions (68). In 
other coronaviruses like TGEV, the N terminal S1 region is involved in receptor binding and the 
S2 domain is responsible for membrane fusion (16). The S1 domain is extremely variable 
whereas the S2 domain is highly conserved (69). The S2 domain is comprised of a hydrophobic 
fusion peptide (FP; residues 891-908), two heptad repeat regions (HR1, residues 978–1117 and 
HR2, residues 1274–1313) and a C-terminal transmembrane region (TM; residues 1328–1350) 
(16, 66). The S1 protein contains a signal peptide (residues 1-18), an N terminal domain (NTD; 
residues 19-233), which exhibits sialic acid binding activity, and a C-terminal domain (CTD; 
residues 477-629), which may interact with cellular receptors (66). 
With its critical role in attachment and entry, S protein is the major target of humoral 
immunity (66, 70). S protein is the major target of virus neutralizing antibodies (64, 71). Several 
studies have shown that vaccination of pigs with full or a truncated form of S protein provides 
protection against infection to some extent and elicits a protective antibody response (72, 73). It 
has been reported that S protein contains multiple neutralizing epitopes in both S1 and S2 
regions, including residues 201-212, 499-638, 636-789 which has been mapped to the S1D 
region (74), 744-759, 756-771, and 1368-1374 which has been mapped to the S2 region (70, 72, 
73, 75-78). 
1.2.7.2 Envelope protein 
PEDV E protein is a component of the viral envelope. The coronavirus E protein is the 
smallest structural protein with a single predicted hydrophobic domain (79). TGEV E protein has 
been shown to have a role in viral budding (80). This small unglycosylated protein appears to 
interact with M protein during envelope formation at the virus assembly phase and aid in 
efficient release (81). Besides the role in virus assembly, E protein has been shown to cause 
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endoplasmic stress and to activate NF-κB, which upregulates IL-8 and Bcl-2 expression (82). 
Overexpression of PEDV E protein has been shown to antagonize IFN production (33). Similar 
to the role of  SARS-CoV E protein, PEDV E protein is known to have an important role in 
pathogenesis (83).  
1.2.7.3 Membrane protein 
M protein is the most abundant structural protein in CoVs, which gives a shape to the 
virion (16). M protein consists of a large globular endodomain, three transmembrane domains, 
and a small extensively N-glycosylated ectodomain (16, 84). The protein is embedded in the 
viral envelope by three transmembrane domains and plays a crucial role in viral packaging and 
budding. M protein usually does not have a signal peptide, and its endodomain has sites for 
interacting with S and N proteins (16). Host immune response to the M protein of CoVs plays an 
important role in pathogenesis and protective immunity (85).  
PEDV M protein is a 27-32 kDa protein with 226 amino acids. The protein is highly 
conserved among different PEDV strains but shares low homology with the M gene of other 
CoVs. Yet, it has high homology with the M gene of TGEV, PRCV, and PDCoV and is not 
considered a good marker for differential diagnosis (86). M protein also contains conserved B 
cell epitopes (87). It has been shown in vitro that PEDV M protein blocks cell cycle progression 
at the S-phase of the cell cycle and its subcellular localization in porcine epithelial cells (88). 
1.2.7.4 Nucleocapsid protein 
PEDV N protein is associated with the viral genome inside the virion, forming 
ribonucleocapsid in a helical structure. N protein is highly conserved among PEDV, and a large 
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amount of N protein is produced in virus-infected cells. It is a multifunctional phosphoprotein of 
approximately 43-50 kDa in size and is crucial for RNA synthesis.  
N protein carries out multiple functions during the viral life cycle. It binds with the 
endodomain of M protein (16, 89). Several studies have shown that PEDV N protein is involved 
in viral nuclear localization, upregulation of interleukin-8 expression, and inhibition of IFNβ 
production, host ER stress, and S-phase prolongation (90-92). However, its role in nuclear 
localization is debatable as reported data are incomplete and have discrepancies between studies 
probably due to the use of different PEDV strains in different cell lines (60). Overexpression of 
N protein has been shown to antagonize IFN production as well (33). 
N protein is the most immunogenic viral protein. Antibodies against N protein are 
detected as early as 7 days post infection; hence, the protein could be a good antigen candidate 
for PEDV diagnosis (86, 93). However, N protein antibody has shown some level of cross-
reactivity with N protein of the TGEV Miller strain (86).  
N protein has been an attractive target for antiviral research. More studies are needed to 
understand the role of N protein in PEDV pathogenesis, regulation of host environment, and 
immune evasion. 
1.2.8 Epidemiology 
The PEDV-associated diarrheic disease was first reported in England and later in 
Belgium in the early 1970s. The virus was isolated for the first time from pigs in Belgium and 
was then classified into the family Coronaviridae based on the morphology observed on electron 
microscopy (2, 94). Since the early 1970s until the 1990s, PED outbreak in Europe has been 
sporadic: in England in the late 1990s, in Hungary in the mid- 1990s, in the Netherlands in the 
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late 1980s and early 1990s, and in Italy in 2005-2006 (4). It was infrequent in Europe and 
disappeared from most countries; hence, the disease did not get enough attention and was not 
registered as a reportable disease by the World Organization for Animal Health (OIE) (26, 95).  
Unlike in Europe, PED became a devastating disease in Asia once it spread. PEDV was 
first identified in China in 1973, soon after the disease was reported in Europe (96). 
Subsequently, severe PED epidemics were reported in Japan and South Korea during the 1980s 
and 1990s (97, 98). Starting in 2010, severe PED outbreaks were reported in China even in pigs 
vaccinated with PEDV prototype strain CV777 in various regions. The new outbreaks have been 
attributed to the emergence of new PEDV ‘variant’ strains that are different from CV777 (96, 99, 
100).  
In the US, PED was first reported in April 2013, and the disease caused by PEDV is 
genetically closely related to the Chinese strains (China/2012/AH2012) identified in 2010-2012. 
By 2014, the newly emerged PEDV spread to US neighboring countries including Canada, 
Mexico, and Columbia (25). By October 2013, highly virulent PEDV, similar to US PEDV, was 
subsequently reported in many Asian countries including Japan, South Korea, Vietnam, Taiwan, 
Thailand, and the Philippines (28, 101-104). Interestingly, after the US PED outbreak in 2013, 
several European countries (Belgium, Netherlands, France, Germany, Portugal, and Italy) have 
reported reoccurrence of PED (96, 105).   
The prototype NA PEDV strains are phylogenetically close to the Chinese strain 
CHN/AH2012, indicating the possibility that the NA strain emerged from the recombination of 
various Chinese strain(s) (5, 8, 26). The group now referred to as G2 also includes other recent 
Chinese, South Korean, and European PEDV isolates, suggesting inter-continental spreading of 
the contemporary PEDV strain. PEDV in this group tends to be more virulent than older isolates 
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as they cause higher mortality in young piglets. At the same time, PEDV with insertions and/or 
deletions in S protein, which has been named S-INDEL variant, has also emerged recently(28). 
The pathogenicity of these strains is generally milder than that of non-S-INDEL strains. While S-
INDEL variants are grouped with non-S-INDEL strains in G2 based on whole genome analysis, 
S gene phylogeny shows that the S-INDEL strains are more closely related to classical PEDV 
strains, i.e., G1 (28).  
PEDV transmits primarily through the fecal-oral route, similar to many enteric pathogens 
(9). The virus mainly replicates in the small intestine, and infected animals have shown shedding 
of a large amount of virus in feces (3, 12). Therefore, feces from the infected animal is the main 
source of the virus transmitted to other naïve animals. In one study, PEDV RNA could be 
detected in feces from experimentally infected pigs for at least 42 days after inoculation; 
however, the experimentally infected pigs were able to infect comingled aged-matched naïve 
pigs only for 14-16 days post-inoculation through fecal shedding (106). Under certain conditions, 
airborne transmission of PEDV within a barn or building may be possible (107). The virus can 
enter farms by subclinical pigs (9), virus-contaminated fomites like trucks/trailers and feedstuff, 
and personnel such as veterinarians, farm workers, and trailer drivers (108-110). Studies have 
shown PEDV RNA detection in milk samples of affected lactating sows (111).  
1.2.9 Virus replication and pathogenesis 
PEDV is known to replicate in the mature intestinal enterocytes, which leads to villous 
atrophy thereby causing malabsorptive watery diarrhea with anorexia and occasional vomiting in 
pigs of all ages (2, 9, 12, 13). The average incubation period is about 24 hours and up to a week 
depending on the field and experimental conditions. Under the experimental condition, infected 
pigs shed PEDV in feces for a long period after clinical diarrhea is ceased. Non-intestinal 
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replication of the virus in infected pigs has not been reported. Diarrhea and dehydration are the 
major causes of death seen in the neonatal pigs (3, 12).  
The severity of the disease depends on animal age and the strain of PEDV. Neonatal pigs 
are unaffected in the early outbreak as reported in Europe (24). However, over time, this 
paradigm has changed, and researchers started to observe more severe disease in piglets. 
Classical Euro-Asian strains (i.e., PEDV in G1) and the US S-INDEL strain tend to cause low 
mortality in piglets (12, 96). However, the US prototype strain (i.e., PEDV in G2) causes severe 
disease and high mortality in the neonatal piglets but less severe disease in weaned pigs.  
Gross lesions are observed exclusively in the intestinal tract in the entire small intestine 
and occasionally in the cecum and colon characterized by atrophic enteritis and transparent 
intestine walls with watery contents in the gut (9, 13, 112). Sometimes, limited virus replication 
in the large intestine and crypt epithelium can also be observed. The gross and histopathologic 
lesions are very similar to those caused by TGEV, another member of the Alphacoronavirus 
genus (12, 13, 15). 
1.2.10 Receptor binding and cellular entry 
Coronaviruses infect a wide range of mammals including humans, pigs, cattle, cats, dogs, 
bats, whales, and birds, but an individual coronavirus generally infects one or a few closely 
related hosts (16, 17). The major target cell of CoVs is intestinal or respiratory epithelium. 
Coronaviruses have been known to bind to a wide range of cell surface molecules by the S 
protein, and such binding initiates virus infection (16). PEDV has been shown to infect only 
swine enterocytes particularly in the small intestine (3, 12, 13). The S1 domain of the S protein 
of several alphacoronaviruses, including TGEV, PRCV, canine coronavirus type II, feline 
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coronavirus type II, and HCoV-229E, are known to utilize aminopeptidase N (APN) as a 
functional cellular receptor (66). PEDV has also been reported to use APN as a functional 
receptor (113, 114). Those studies involved mostly overexpression of APN in non-permissive 
cell lines. Also, transgenic mice expressing porcine aminopeptidase N (pAPN) have been shown 
to be susceptible to PEDV infection (115). However, the role of APN as a functional receptor for 
PEDV has been controversial and recently disputed. It has been reported that APN is not a 
functional receptor but promotes virus infectivity by its aminopeptidase activity (116, 117). In 
another study, when APN expression in PEDV-susceptible ST cells and human cell lines (Huh7 
and HeLa) was knocked out by CRISPR/Cas9 treatment, those cells lines were resistant to 
infection by TGEV and HCoV-229E, but the treatment had no effect on PEDV infection, 
suggesting that APN is not essential for PEDV entry (117). Another study has suggested that 
heparin sulfate acts as an attachment receptor which helps initial attachment of PEDV to 
susceptible cells (118). The same study showed that treating PEDV with either heparin or an 
analog of heparin sulfate or removing cell-surface heparin sulfate with heparinase I lead to 
decreased PEDV infection.  
Aminopeptidase N, also known as CD13, is a 150-kDa glycosylated type II 
transmembrane protein with multiple biological functions and is highly abundant on the apical 
membrane of mature enterocytes (119). Porcine APN (pAPN) is naturally expressed on swine 
enterocytes and was shown as a cellular receptor for PEDV S1 binding (120). pAPN is also 
abundantly found on the surface of epithelial cells of the kidney and the respiratory tract (120). 
PEDV may require a higher level of pAPN expression on susceptible cells for infection since 
non-permissive cells like swine testicular (ST) and canine kidney (MDCK) overexpressing 
pAPN has shown to support PEDV replication. Vero cells derived from an African Green 
17 
 
monkey kidney is the only cell line that is permissive to PEDV and has been used for a long time 
to isolate and grow PEDV (121). Interestingly, Vero cells do not express APN as confirmed by 
several studies (116, 122, 123). These data support that other receptor(s) should be involved in 
PEDV entry into the target cells. The exact receptor and the entry of PEDV is yet to be 
identified.  
PEDV exhibits a complex interaction with cell surface molecules. Besides its interaction 
with pAPN, PEDV has been shown to bind with sialic acid (124, 125) like many other 
coronaviruses (126). PEDV S1 shows a higher affinity for N-acetylneuraminic acid (NeuAc), a 
predominant sialic acid found on many mammalian cells (125). It was shown that the N-terminal 
region of PEDV S protein (1-320) bound to sialic acid, and sialic acid binding activity of S 
protein facilitated virus infection (66). However, it is not clear how sialic acid binding promotes 
PEDV entry into host cells and if the sialic acid binding capacity of S protein differs among 
different PEDV strains (66). Furthermore, recent reports have shown that PEDV still enters cells 
and replicates even though a large deletion exists in the same N-terminal region that reportedly 
binds to sialic acid (57, 66, 127). The majority of genetic variations in the S protein among S-
INDEL strains occur in the N terminal region. All amino acid insertions and deletions in such 
strains have also been found in this region (25, 128). All these observations cast doubt on the 
role of sialic acid in the receptor binding and infection of PEDV. 
1.2.11 Proteolytic activation and tissue tropism 
Unlike TGEV and many other CoVs, PEDV needs supplementation of trypsin in the 
media to be propagated in an in vitro cell culture system (121). In contrast, cell-adapted PEDV, 
such as DR13 and SM98 vaccine strains, can be propagated without trypsin supplementation in 
cell culture media (66). Differences in S protein sequences have been investigated to determine 
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the virus’s dependency on trypsin (67, 129). Trypsin has been shown to be required for cell-cell 
fusion and syncytia formation, suggesting that trypsin plays a role in the activation of S protein’s 
membrane fusion potential and the release of progeny virus from infected cells in addition to its 
role in virus entry (67, 121, 129).  
Coronavirus infection is initiated when the virion binds to cellular receptors. The 
interaction between viral S protein and its respective receptor determines the host specificity and 
tissue tropism (16). Coronavirus membrane fusion with host cell membrane happens after the 
conformational changes in S protein. Conformational changes occur after receptor binding as 
well as changes in pH. Similar to other class I fusion proteins, CoV’s S protein requires 
proteolytic activation to initiate its fusion potential (65, 66). S proteins of PEDV and other 
alphacoronaviruses are presented in their uncleaved form (i.e., inactive form). The cleavage is 
believed to occur at the cell surface or in the endosome compartment during virus entry. It has 
been shown that proteolytic activation of S protein by trypsin only happens after the receptor 
binding stage (67, 123, 130). Furthermore, prior treatment of PEDV with trypsin before receptor 
binding did not enhance the infectivity of the virus (67). All these observations suggest that 
virus-cell interaction is necessary to expose the cleavage site of S protein, which would prevent 
unnecessary activation of the S protein fusion system in the protease-rich intestinal environment. 
This strict trypsin requirement by PEDV for cell entry and release are likely supplied by 
intestinal proteases generated by intestinal epithelial cells. It could be the reason that PEDV 
infection is restricted to the gastrointestinal tract (131). More investigations, however, are 





1.2.12 Innate immunity 
Three different interferons (IFNs) are known to play a role in antiviral innate immunity: 
type I (IFN-α or IFN-β), type II (IFN-γ), and type III (IFN-λ) IFNs (132). In pigs, type I IFNs are 
encoded by as many as 17 different genes (133). After the viral infection, host early innate 
immune response involves the production of type I IFNs and induce an antiviral response in the 
infected cells as well as the uninfected neighbor cells in the intestine (4, 134). Interferon γ is the 
only type II IFN reported to play a role in swine and produced by immune cells. PEDV and other 
CoVs have several strategies to evade the host innate antiviral response which involves several 
structural and non-structural proteins (30). In SARS-CoV at least 11 viral proteins have been 
shown to play as type I IFN antagonist. Similarly, in a recent study for PEDV, at least 10 viral 
proteins have been shown to act as type I IFN antagonists (30, 33). Studies have shown 
coronavirus nsp I as a multifunctional IFN antagonist (30). Still, there are many fundamental 
questions about antiviral immunity particularly in intestine need to be addressed, particularly the 
role of IFN in modulating innate intestinal immunity. 
Natural killer (NK) cells also play a role in the innate antiviral response. This function, 
however, is not fully developed at birth. This may explain why piglets which have less NK cell 
activity and fewer IFN-producing NK cells are more susceptible to PEDV and develop the more 
severe disease after PEDV infection compared to weaned pigs (135). This corroborates with our 
group’s age-dependent susceptibility finding from the pathogenesis study involving both piglets 
and weaned pigs (12, 136). 
1.2.13 Adaptive immunity 
  The adaptive immune response to PEDV and CoVs involves secretory immunoglobulins 
and cytotoxic T cells (134, 137). Mainly secretory IgA (sIgA) plays an important role in the 
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immune response against enteric viruses. Localized sIgAs prevent attachment of viruses and 
neutralize them. The sIgAs are produced by the lymphocytes in the lamina propria of the small 
intestine. In the lamina propria of the small intestine, IgA-secreting lymphocytes against PEDV 
are detected as early as 21 days post-infection. The study showed that the detection of IgG and 
IgA antibodies in serum correlates with the development of a protective immune response 
against the same strain of virus (138).  
In terms of cellular immunity against swine enteric CoVs, T helper cells assist the 
cytotoxic T cells to target the virus as well as support the production of antibodies by B-
lymphocytes. The peak level of CD4+ T cells is observed in mesenteric lymph nodes after 21 
DPI, which correlates with IgA and IgG antibody production in serum (138). In pigs, Tγδ-cells 
also play this role and are predominant in the intraepithelial layer of the intestine (139). The 
majority of T-cell epitopes in swine enteric CoVs have been demonstrated in S and N proteins 
(140, 141). 
The disease caused by PEDV is more severe in neonates whose immune systems are not 
well developed. Also, the in-uterus transfer of immunoglobulins does not occur from the swine 
placenta. Therefore, lactogenic immunity is the main source of protection (142). Maternal 
antibodies (sIgA, IgG, and IgM) passively transferred to piglets through colostrum and milk. IgG 
is the main immunoglobulin in colostrum and is absorbed in neonate pigs within the first 24-48 
hours of life (143). Similarly, sIgA is predominant in milk and is produced by antibody-
producing cells in mammary glands of sows (142). Various strategies, such as administration of a 
live-virus vaccine, killed-virus vaccine or subunit vaccine or feedback of infectious material 
from the same farm have been used to try to enhance maternal immunity in sows. Enhanced sIgA  
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production is seen when sows are exposed to the virus through a mucosal surface. Thus, the best 
route of vaccination to enhance effective maternal immunity against PEDV is the oral route (134, 
144). 
1.2.14 Antibody responses 
All the major structural proteins of PEDV (S1, N, and M, with the exception of non-
reactive E protein) have been shown to be immunogenic. The antibody response pattern against 
various viral proteins has been found to be similar (86).  
 PEDV-specific antibodies have been detected in serum and oral fluid by ELISA. Under 
experimental conditions, pigs have been shown to develop PEDV-specific antibodies in serum as 
early as 7-10 days (86, 145). IgM antibody against N protein peaked at 7 dpi and started to 
decline, whereas the anti-S protein IgM antibody response peaked at 14 dpi and started to 
decline. In comparison, N- and S-specific IgG antibodies became detectable starting at 7 dpi and 
peaked at 21 dpi and 14 dpi, respectively. Then these antibodies started to decline except for 
anti-N IgG antibody, which remained at a higher level up to 43 dpi. The S-specific IgA antibody 
response was similar to the anti-S IgG antibody response, i.e., first detected at 7 dpi, peaked at 14 
dpi and detectable for six months (146). IgA was shown to be the predominant antibody in oral 
fluid. Oral fluid IgG and IgA ELISA antibodies peaked at 21 and 35 dpi, respectively, and 
started to decline at different rates.  
Neutralizing antibodies against PEDV was detected starting 7-14 dpi, peaking on 21 dpi, 
and started to decline (146, 147). Level of ELISA antibody against PEDV S and M proteins 
correlated with neutralizing antibodies (148). This is particularly important because neutralizing 
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epitopes have been reported to be located in S protein, highlighting its clinical relevance. The 
level of neutralizing antibodies seems to remain high for at least six months after infection (149).  
In another study, antibodies against S protein were detectable for a longer period than 
antibody against N protein in the sera of PEDV infected pigs (150). PEDV S1-based fluorescent 
microbead-based immunoassay (FMIA) assays have shown the best diagnostic sensitivity for 
antibody detection with no cross-reactivity detected against TGEV, PRCV, or PDCoV antibodies 
(86). However, the concern with using S protein is the different antigenicity in the S epitope 
among various PEDV strains (112, 151). S genes mutate frequently under the pressure of herd 
immunity. In contrast, PEDV whole virus-, N-, or M-based assays have shown to cross-react 
with TGEV and PRCV antibodies (86). Studies using swine antibody have shown that the TGEV 
Miller strain, but not the Purdue strain, cross-reacts with PEDV (86). The cross-reactivity 
seemed to be mediated by at least one antigenic site at the N terminal of the TGEV N protein 
(112). However, virus neutralization (VN) assays do not demonstrate cross-reactivity between 
TGEV and PEDV strains (112). 
1.2.15 Immunity 
To date, only one serotype is known to exist among PED viruses based on evaluation of 
cross-neutralization using hyperimmune and convalescent swine sera. However, antigenic 
variations between classical strains (G1) and emerging highly pathogenic strains (G2) of PEDV 
have been demonstrated by various serologic evaluations (102, 112, 151). In a recent study, sera 
from pigs infected with a variant strain recognized homologous and heterologous strains using 
PEDV S1-based indirect ELISA. However, neutralizing antibody titers of the sera were higher 
against the homologous strain than the heterologous strain (152). Since these studies were 
performed in vitro, a direct translation of the study observations to in vivo protection may be 
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difficult due to various factors including cellular immunity and maternally-derived passive 
immunity.  
The protective immunity to homologous re-challenge has been evaluated to some extent. 
Prior research showed that homologous re-challenge did not result in re-infection of pigs with 
existing immunity from the previous infection (106). Cross-protective immune response in 
nursing piglets infected with US PEDV S-INDEL and challenged with a US prototype PEDV 
strain has been studied, showing that the S-INDEL strain partially protected against the prototype 
US PEDV strain (153). Immunofluorescence and VN assays have demonstrated two-way 
antigenic cross-reactivity and cross-neutralization among the PEDV strains tested (152, 153). 
Various US PEDV isolates showed conserved antigenicity, suggesting recent isolates might be 
better vaccine candidates. A good correlation between VN and ELISA results has been reported. 
Serum with higher VN activity also had a higher IgG ELISA titer (148). However, circulating 
antibody level may not reflect the protective level of antibody in milk for piglets (154). Also, the 
extent of protection by circulating antibodies to the piglets is still not clear (155). The immune 
correlates of protection have not been elucidated well and need to be further studied. 
Concerning passive immunity, single pre-farrowing infection of gilts resulted in a slight 
increase in serum IgG ELISA and VN antibodies but not IgA ELISA antibody. In this group, a 
low antibody response in colostrum and milk was observed. In contrast, twice infection of gilts 
resulted in a significant increase in IgA and VN titers in milk samples compared to the single 
infected group (156). Another study showed that VN antibodies were present at a higher level in 
colostrum and milk than in serum. Neutralizing activity in colostrum and milk was highly 
correlated with IgA but not IgG, and the IgA antibody was primarily against S protein (70). 
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Further virus challenge studies in piglets are necessary to understand lactogenic immunity and 
protection and to formulate an effective vaccination protocol.  
 
1.2.16 Prevention and Control 
Several strategies have been employed to control PED, including biosecurity, 
vaccination, and immunoprophylaxis. A combination of all of these strategies at various levels 
effectively helps to prevent disease in piglets and virus shedding (3). Strict biosecurity measures 
are a very important safeguard against emerging pathogens like PEDV. The measures include 
disinfection of all the fomites associated with the farm, shower in/shower-out practice, strict 
regulation of incoming and outgoing traffic including disinfection of all the trucks and trailers 
used in the transport of animals, and isolation and quarantine of newly arrived replacement 
animals (26, 134).   
In seronegative breeding farms, vaccination of pregnant sows is very important to induce 
lactogenic immunity and prevent morbidity and mortality of piglets. In the absence of licensed 
vaccines, ‘feedback’ (i.e., controlled exposure to live virus) has been commonly practiced to 
establish protective immunity. The effectiveness of this method in providing the protective 
immunity to piglets, however, varies. Furthermore, the potential risk of spreading other 
pathogens exists because of the nature of materials to be used for feedback (157).  
Various attenuated and killed virus vaccines are used for PED prevention and control in 
Asia with varying success (26). In North America, three conditionally licensed vaccines are 
available. The first vaccine was developed by Harrisvaccines and was conditionally licensed in 
the US. This vaccine is based on SirraVaxSM RNA particle technology and uses codon optimized 
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full-length S gene of PEDV (157). The second vaccine was developed by Zoetis, which consists 
of the inactivated whole virus with formulated adjuvant. The Vaccine and Infectious Disease 
Organization-InterVac in Canada developed the third vaccine. The vaccine contains inactivated 
virus with proprietary adjuvant (158). All of these available PEDV vaccines have low to 
moderate effectiveness due to antigenic differences between the vaccine strains and field strains 
(26). Several studies have shown that oral administration of live attenuated PEDV is more 
effective in boosting or protecting pregnant sows and their piglets (9, 159). In addition, previous 
studies have shown that PEDV vaccines induce better IgA and IgG in herds previously exposed 
to PEDV compared to the same vaccines in naïve herds, highlighting the importance of 
‘prime/boost strategy’ (134, 160).  
Porcine epidemic diarrhea can be effectively controlled with combinations of 
vaccination, good biosecurity, and immunoprophylaxis. Yet, lactogenic immunity is the key to 
prevent the significant loss of baby pigs. However, in the case of emerging strains or 
recombinant virus, the traditional way of virus isolation and inactivation and/or attenuation 
becomes obsolete as it takes more time. More innovative vaccine-producing technology, such as 
rapid reverse genetics, RNA particle, DNA, subunit using recombinant protein and viral-viral 
vectored approaches, should be in place to combat emerging coronaviruses (4, 26, 27, 157, 161). 
1.2.17 Conclusion and perspectives 
Porcine epidemic diarrhea is a highly contagious enteric disease of swine and can cause 
high pre-weaning mortality to many naïve farms, which can lead to a significant economic 
hardship to producers. Vaccines have been developed and widely used, but their efficiency has 
been limited. PEDV goes through continuous genetic mutations, and recombination events occur 
frequently among PEDV strains and occasionally with other coronaviruses as well. This leads to 
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antigenic changes in the virus, which enables it to evade the immune system, and continues to 
impede effective control of the disease. Since its emergence in the US in 2013, our knowledge 
and understanding of PEDV pathogenesis, immune response, genomics and proteomics, 
diagnostics, and disease ecology and control have been greatly enhanced. Nevertheless, the 
immunobiology related to virus infection, detailed virus-host interactions, and the mechanism of 
virus attenuation largely remain unexplored. The failure of classical PEDV-based vaccines in 
Asia and the lack of attenuated vaccines against the emerging strains highlight the necessity of 
the development of new vaccines against highly virulent PEDV strains. With the availability of 
novel reverse genetic systems for the manipulation of PEDV genomes, it is now possible to 
foster the development of next-generation vaccines to combat further PED outbreaks. In order to 
accomplish this, a better understanding of PEDV-host interaction is necessary, which will lead to 
formulating effective prevention and control strategies. 
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2.1  Abstract 
A challenge study was conducted in weaned pigs (n=98) to assess clinical and antibody 
responses to infection/re-infection by porcine epidemic diarrhea virus (PEDV). Pigs were 
orogastrically inoculated with PEDV at 1x103 PFU/ml or cell culture media at 0 and/or 56 days 
post inoculation (dpi) and were monitored for clinical signs and fecal virus shedding after each 
challenge. Sera and oral fluid (OF) samples were collected periodically until 76 dpi (20 days 
after re-challenge) and tested for anti-PEDV antibodies by indirect fluorescent antibody (IFA) 
test, virus neutralization (VN) test and ELISA which was optimized for antibody isotyping. The 
viral protein reactivity of antibody was determined by an immunofluorescence assay against 
BHK-21 cells transiently expressing each of the PEDV structural proteins. Pigs became diarrheic 
after the first inoculation regardless of age but were not diarrheic when re-exposed at 56 dpi, 
demonstrating that the immunity by prior infection provided clinical protection from subsequent 
homologous challenge at 2 months post inoculation. Pigs developed virus-specific antibodies of 
all major isotypes by 7-14 dpi but displayed different antibody kinetics and profiles between 
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serum and OF. While serum antibodies started to decline steadily after 28 dpi, IgA in OF 
remained at a high level after 35 dpi until re-inoculation, suggesting that detection of IgA in OF 
may provide a better prediction for protective immunity against subsequent challenge. All major 
structural proteins of PEDV were immunogenic except E protein. S protein appeared to be 
associated with the development of serum VN antibody while N protein can be a good antigen 
basis for antibody detection. 
2.2  Introduction 
Porcine epidemic diarrhea virus (PEDV) is the causative agent of effusive diarrhea in 
pigs of all ages and significant mortality in pre-weaning pigs (1-5). In naïve herds, pre-weaning 
mortality can reach nearly 100%. The disease (PED) was first recognized in the United Kingdom 
in 1971, then emerged and disappeared from Europe over the years (4, 6). The virus, on the other 
hand, has become endemic in Asia once introduced in the early 1990s and has caused a 
significant production problem in many Asian countries. The first PED outbreak occurred in 
United States swine in 2013 (2). After the US outbreaks, PED has also been reported in Canada, 
Mexico, South America, and Europe (4, 7-10).  
Porcine epidemic diarrhea virus is an enveloped, single-stranded, positive-sense RNA 
virus belonging to the genus Alphacoronavirus in the family Coronaviridae along with 
transmissible gastroenteritis virus (TGEV), porcine respiratory coronavirus, and a couple of 
other coronaviruses causing enteric diseases in pigs (11-15). The viral genome is approximately 
28 kb with a 5’ cap and a 3’ poly-A tail. The genome consists of seven open reading frames 
(ORFs) that encode four structural proteins and three major non-structural proteins, which are 
arranged on the genome in the order 5’-replicase (1a/1b)–S-ORF3–E–M–N–3’. Genes for the 
major structural proteins, such as spike (S, 180–220 kDa), membrane (M, 27–32 kDa), 
42 
 
nucleocapsid (N, 58 kDa) and small membrane (E, 7 kDa), are located downstream of the 
polymerase gene, which takes up almost two third of the genome (7, 11, 12, 16).  
After its first emergence in the US, PED spread rapidly across the country and resulted in 
the death of 5-8 million pigs, causing significant economic losses (2, 17, 18). In naïve swine, 
PED is clinically manifested by acute and perfused diarrhea with occasional vomiting in neonatal 
piglets resulting in dehydration and death in 2-4 days. PEDV infection also caused significant 
morbidity but low mortality in weaned pigs (2, 3, 5, 19). Significant weight loss in growers has 
been a productivity issue in affected farms (19, 20).  
For laboratory diagnosis, PCR assays have been the main tool to detect PEDV in various 
sample matrices (19). Subsequently, various serological assays have been developed using 
contemporary strains of PEDV, including indirect fluorescent antibody (IFA) test, serum-virus 
neutralization (SVN) test, enzyme-linked immunosorbent assay (ELISA), and fluorescent 
microsphere immunoassay (21, 22). Serology is one of the key tools utilized in understanding 
disease epidemiology, surveillance and disease control (11). Detection of anti-PEDV antibodies 
has been evaluated in sera and oral fluids from swine with naturally occurring or experimentally 
induced PEDV infection (21-26). However, the detailed humoral immune response against 
PEDV challenge/re-challenge and serological correlates of protective immunity have not been 
described in detail under experimental conditions. In addition, the temporal profile of the 
antibody response to PEDV structural proteins has not been characterized. The objectives of the 
following study were to: 1) assess the ontogeny of antibody response in pigs following 
experimental PEDV infection/re-infection using sera and oral fluids; 2) characterize the protein 
specificity of antibody response over time; 3) determine if prior infection confers protective 
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immunity against subsequent challenge; and 4) correlate antibody response with protection from 
subsequent infection. 
2.3  Material and Methods 
2.3.1  Study design 
The experimental design was approved by the Iowa State University Institutional Animal 
Care and Use Committee (protocol log #6-13-7593-S). Ninety-eight 3-week-old weaned pigs 
were sourced from a single commercial, crossbred farrow-to-wean farm with no known prior 
exposure to PEDV and housed in the Livestock Infectious Disease Isolation Facility at Iowa 
State University. Pigs were also free of porcine reproductive and respiratory syndrome virus and 
TGEV infection/exposure. The pigs were acclimatized for 3 days, and the acclimation procedure 
was described elsewhere (19, 27).  
Pigs were first allocated randomly into two groups: challenged (n=56) and sham control 
(n=42). At 56 days post inoculation (dpi), each group was further divided into two groups: 
challenged (n=12) and sham control (n=9). Overall, the study had four treatment groups: a) dpi 0 
challenged (C-N); b) dpi 56 challenged (N-C); c) dpi 0 challenged and re-challenged at dpi 56 
(i.e., 8 weeks after the first challenge) (C-C) and; d) sham control (N-N). The study ran for 76 
and 20 days from the first and second inoculation, respectively. The groups were housed in the 
same facility but separated by room and ventilation system. Pigs in each room were confined by 
pens (14 pigs/pen) on a solid floor that was rinsed daily, fed a balanced diet ad libitum based on 
weight, and given free access to water.  
All pigs were bled prior to inoculation (dpi 0). Three control and four challenged pigs 
were randomly selected for necropsy on various dpi as shown in Table 1. Blood samples were 
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collected from these pigs before euthanasia and processed to obtain sera. Fresh and formalin 
fixed sample collection at necropsy included: small intestine, cecum, colon, mesenteric lymph 
node, tonsil, stomach, lung, heart, liver, spleen, and kidney. Serum was also collected from all 
remaining pigs weekly. Fecal swabs were collected on dpi 0, daily for the first week post-
inoculation, and every seven days until the end of the study at dpi 76 from all remaining pigs. 
Oral fluids were collected per pen starting at 1 dpi daily through 7 dpi as previously described 
(28). Thereafter, oral fluids were collected twice weekly through 52 dpi. After re-inoculation at 
56 dpi, oral fluids were collected from all groups daily for a week and then twice weekly until 
the end of the study. The oral fluid (OF) samples were immediately frozen at -80°C until tested. 
Serum and OF samples were tested for antibody kinetics and protein specificity profile.  
2.3.2  Virus and cell 
A US prototype PEDV isolate (US/Iowa/18984/2013; GenBank accession #KF804028) 
(7) was propagated in Vero cells (ATCC® CCL-81) as previously described (19, 29) and used to 
inoculate pigs as well as in laboratory assays. Briefly, Vero cells were grown in Dulbecco 
Minimum Essential Medium  (DMEM, Thermofisher Scientific, Waltham, MA) supplemented 
with 10% fetal bovine serum(Atlanta Biologicals, Flowery Branch, GA), 0.3% tryptose 
phosphate broth (Thermofisher Scientific, Waltham, MA), 0.02% yeast extract (Sigma Aldrich, 
St. Louis, MO), 100 unit/ml penicillin (Thermofisher Scientific, Waltham, MA) , 100 µg/ml 
streptomycin (Thermofisher Scientific, Waltham, MA) (hereafter, growth media). Viral infection 
of the cells was carried out in the presence of the growth media supplemented with 10 µg/ml of 
trypsin 250 (Thermofisher Scientific, Waltham, MA) (hereafter, post-inoculation media). The 




2.3.3  Antibody response to PEDV infection 
The temporal appearance of anti-PEDV antibodies in swine sera was assessed using 
indirect fluorescent antibody (IFA) and virus neutralization (VN) tests after experimental 
inoculation and subsequent challenge over the course of 76 days after the first inoculation.  
2.3.4  Indirect fluorescent antibody (IFA) test 
The IFA test was performed on serially diluted serum against virus-infected Vero cell 
monolayers as previously described (2, 5, 19). For IFA antigen preparation, confluent Vero cell 
monolayers grown in 96-well plates (ThermoFisher Scientific, Waltham, MA) were inoculated 
with 100 µl/well of PEDV at 1000 plaque-forming unit (PFU) per 1 ml and incubated at 37°C 
with 5% CO2 supply. Twenty-four hours later, the inocula were removed and cells were fixed 
with cold 80% acetone-ethanol solution for 10 min at ambient temperature. Plates were air-dried, 
sealed and stored at -80°C until used. 
For testing, each serum was first diluted 1:10 and serially diluted 2-fold (1:20 to 1:1280); 
then 100 µl of each diluted serum sample was added to each well of the IFA plates. After 1-hr 
incubation at 37°C, the sera were removed and wells rinsed three times with 0.01M phosphate 
buffered saline (PBS, pH 7.4; ThermoFisher Scientific, Waltham, MA). Then 50µl/well of 1:50 
diluted goat anti-swine IgG (γ) antibody conjugated with FITC (Kirkegaard & Perry 
Laboratories, Inc., Gaithersburg, MD) was added to each well and incubated at 37°C for 1 hr. 
Plates were then rinsed three times with PBS, and cell staining was examined under a fluorescent 
microscope. The positive signal (bright apple-green cytoplasmic fluorescence) at a serum 




2.3.5  Virus neutralization (VN) test 
Neutralizing activity of serum samples was accessed by observing the presence and 
absence of cytopathic effect (CPE) of PEDV in cells inoculated with a virus-serum or a virus-OF 
mixture. Both serum samples and OF were first heat inactivated at 56°C for 30 min. Sera were 2-
fold serially diluted from 1:2 to 1:512 in 96-well plates with a volume of 100 µl per well after 
dilution while OF samples were diluted 1:1. Subsequently, each sample was mixed with an equal 
amount (100 µl) of 1000 PFU/ml of PEDV and incubated for 1 hr at 37°C. Then 200 µl of the 
sample-virus mixture was transferred to 96-well plates with confluent Vero cell monolayers, and 
the inoculated cells were incubated for 1 hr at 37°C. The cells were washed twice with the post-
inoculation media and incubated with 100µl/well of such media for 3-5 days at 37°C with 5% 
CO2. Virus-specific CPE was examined under a bright field microscope. The reciprocal of the 
highest serum dilution with no CPE as compared to the negative serum control was defined as 
the VN titer of each sample. Each sample was tested in duplicate, and four control wells were 
used on each assay, including a positive hyperimmune pig serum, a negative control pig serum, a 
virus control (no antibody), and DMEM media (no virus, no antibody). The virus inoculum was 
back titrated in Vero cells in 6-well plates to confirm the virus titer (PFU/ml) as previously 
described (7, 27). Briefly, each sample was serially 10-fold diluted in post-inoculation media and 
inoculated into Vero cells grown in 6-well plates as described previously and virus titers 
expressed as PFU/ml. 
2.3.6  Profiling of antibody isotypes in sera and oral fluids 
An enzyme-linked immunosorbent assay (ELISA) was employed to characterize the 
isotype profile of anti-PEDV antibody response in serum and oral fluid samples of pigs over time 
after experimental inoculation. ELISA plates were prepared using whole PEDV as previously 
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described (7, 19). In brief, the virus-containing cell culture supernatant was first centrifuged at 
4,000 x g for 15 min to remove cell debris. Subsequently, the virus was pelleted by 
ultracentrifugation at 140,992 x g for 3 hr, after which the pellet was washed once with sterile 
Gibco™ PBS (0.01M, pH 7.4, Thermofisher Scientific, Grand Island, NY). The purified virus 
was resuspended in 1/100 of the original volume in PBS and stored at -80°C until used. 
Polystyrene 96-well plates (Nunc, ThermoFisher Scientific, Agawam, MA) were coated (100 µl 
per well) with viral antigens in PBS and then incubated at 4°C overnight. After incubation, plates 
were washed 5 times, blocked with 300 µl per well of PBS solution containing 1% bovine serum 
albumin (Jackson ImmunoResearch Inc., West Grove, PA), and incubated at room temperature 
for 2 hr. Plates were then dried at 37°C for 4 hr and stored at 4°C in a sealed bag with desiccant 
packs until used.  
ELISA conditions, including coating and blocking conditions, reagent concentrations, 
incubation times, and buffers, were optimized for detection of anti-PEDV IgM, IgA, and IgG 
antibodies in serum and oral fluids prior to this study. Test samples, plate positive and negative 
controls, i.e., antibody-positive (dpi10) and negative (dpi 0) experimental serum samples, were 
run in duplicate on each ELISA plate. Serum and OF samples were diluted 1:50 and 1:1, 
respectively, after which plates were loaded with 100 µl of each diluted sample per well. Plates 
were incubated at room temperature for 1 hr and washed 5 times with PBS. Then, 100 µl of 
peroxidase-conjugated goat anti-pig IgG (H+L) antibody (Jackson ImmunoResearch Inc., West 
Grove, PA) diluted 1:25,000 or goat anti-pig IgA (H+L) (Bethyl Laboratories Inc., Montgomery, 
TX) diluted 1:2,500 was added to each well and the plates incubated at room temperature for 1 
hr. After a washing step, the presence of antigen-antibody mixtures was visualized by adding 100 
µl of TMB (tetramethylbenzidine-hydrogen peroxide) substrate solution (Dako North America, 
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Inc., Carpinteria, CA) to each well. Plates were incubated at room temperature for 5 min and 
then 50 µl/well of stop solution containing 1M sulfuric acid (Thermofisher Scientific, Waltham, 
MA, USA) was added to stop the colorimetric reaction. Optical density (OD) of each well was 
measured at 450 nm wavelength using an ELISA plate reader (Biotek® Instruments Inc., 
Winooski, VT) operated with commercial software (GEN5TM, Biotek® Instruments Inc.). Net 
OD values from samples (i.e., sample OD – ODs from blank and negative control) were 
calculated and used for data analysis.  
2.3.7  Viral protein reactivity of antibody response 
 The reactivity of pig sera with each of PEDV structural proteins was determined by 
immunofluorescence microscopy on BHK21 cells transiently expressing each recombinant viral 
protein. All PEDV structural protein genes (i.e., S, S1, E, M, and N) were cloned into a PXJ41 
expression vector which was kindly provided by Dr. Dongwan Yoo at the University of Illinois 
in Urbana-Champaign, IL. PEDV structural proteins were then transiently expressed via 
transfection into BHK21 cells using those plasmids with each of the PEDV structural protein 
genes (30). For immunofluorescence microscopy, serum samples from different dpi were diluted 
1:50 and inoculated onto fixed BHK-21 cell monolayers prepared in plates along with known 
positive and negative control pig sera. After the 1hr incubation, the sera were removed and plates 
rinsed three times with Gibco™ PBS. Then 50µl/well of 1:100 diluted goat anti-swine IgG (γ) 
antibody conjugated with FITC (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) was 
added to each well and incubated at room temperature for 1 hr. Plates were then rinsed three 




2.3.8  Statistical analysis  
The statistical difference among treatment groups for the serum and oral fluid ELISA 
(i.e., level, duration, isotypes) was assessed using one-way ANOVA followed by Pearson’s chi-
square test to determine the difference in the number of seropositive by dpi, with p value <0.05 
considered significant.  The analyses were done using JMP software (SAS Institute Inc., Cary, 
NC). 
2.4  Results 
2.4.1  Clinical assessment of pigs after first infection and re-infection 
All pigs showed no signs of diarrhea or depression prior to inoculation. While control 
pigs (both N and N-N groups) continued to have normal feces for the duration of the study 
(Table 2), PEDV-challenged 3-week-old pigs (25% up to 70% at any given dpi) had semi-solid 
to watery feces starting at 2 dpi, with most pigs recovering by 10 dpi. Virus shedding in feces 
was detected by PCR in more than 60% of the pigs until 24 dpi regardless of clinical signs (Fig. 
1). Details of clinical response, virus fecal shedding and histological observations on small 
intestine during 35 dpi have been reported previously (19).  
When the remaining previously exposed pigs (n=12) were re-inoculated with PEDV at 
day 56 after the initial inoculation (11 weeks of age), no diarrhea was observed in any of the pigs 
(C-C group) although fecal shedding of the virus was detected by PCR in all of the pigs at some 
points within the first 10 days after inoculation. No fecal shedding was detected in any of the 
pigs at 21 dpi (Fig. 1). In contrast, 10-70% of nine age-matched naïve pigs (N-C group) became 
diarrheic from 3 to 7 dpi when exposed to the virus and then started to recover. All of the pigs 
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shed PEDV in feces until 7 dpi as determined by PCR, and 15% of the pigs still shed the virus at 
21 dpi. 
2.4.2  Serum antibody responses to PEDV 
Antibody response against PEDV was detected by IFA test as early as 7 dpi (Fig. 2). The 
IFA titer peaked at 21 dpi and subsequently started to decline over time. After the re-inoculation 
at 56 dpi, the IFA titer increased, implying the anamnestic immune response. In comparison, 
neutralizing activity (≥1:2 VN antibody titer) against PEDV was detected in sera at 14 dpi and 
peaked at 21 dpi. VN antibodies remained at a similar titer over subsequent dpi’s but overall titer 
was low. The VN antibody titer in serum increased after re-inoculation at 56 dpi.  
2.4.3  Isotype profile of antibody responses 
As shown in Figure 3, all sera collected at 0 dpi were negative for PEDV-specific IgG, 
IgM, and IgA. All three isotypes of antibody were detected in the sera starting at 7 dpi. IgM 
antibody peaked at 7 dpi, remained the same until 14 dpi, and declined to the lower level at 21 
dpi. IgG serum antibody peaked at 28 dpi, declined gradually over subsequent dpi and was still 
detectable at 56 dpi. IgA antibody in sera peaked at 21 dpi, gradually declined in the subsequent 
dpi, and was still detectable at 56 dpi. After re-inoculation at 56 dpi, both IgG and IgA antibody 
titers spiked rapidly while IgM level remained unchanged.  
In oral fluids, OD values for both IgG and IgA were statistically greater for the 
challenged group than control group beginning at 10 dpi and remained significantly greater 
through the rest of the study duration as illustrated in Figure 4. IgG and IgA ELISA antibodies 
peaked around 21 and 35 dpi, respectively, and thereafter started to decline at different rates.  
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The IgA antibody level remained high in oral fluids through 56 dpi, while IgG antibody 
gradually declined after 35 dpi. 
2.4.4  Reactivity of serum antibody responses to PEDV structural proteins 
All of the major structural proteins of PEDV except E protein were immunogenic (Table 
3). Among the viral structural proteins, antibody response against S, S1 and N proteins was 
detected as early as 7 dpi after the first inoculation; however, antibody response against M and E 
proteins was not detected. After re-inoculation, antibody to the M protein became detectable in 
the previously inoculated pigs whereas antibody to E protein remained undetectable. Antibody 
levels to S, S1 and N proteins seemed to be increased by re-inoculation since stronger 
fluorescence intensity was observed. 
2.5  Discussion 
The main objective of this study was to characterize clinical and antibody responses in 
pigs following PEDV infection/reinfection. Clinically, naïve pigs (N and N-C groups) became 
diarrheic starting at 2 or 3 dpi when orally exposed to the same dose of PEDV regardless of their 
age, i.e., 3- versus 11-week-old (Table 2) and was resolved by 10 dpi in both groups, which is in 
a general agreement with previous reports (25, 31). Fecal shedding of the virus, however, 
continued for some time (2-3 weeks) in these recovered pigs (i.e., non-clinical) as previously 
reported (19, 23). While clinical manifestations were not significantly different between the two 
age groups, older pigs displayed virus clearance faster than younger ones. At 21 dpi, 15% of the 
older age group shed the virus in feces whereas 69% of the younger age group still shed the virus 
in their feces (Fig. 1). In addition, viral titers in feces were lower in older pigs than younger pigs 
during the period of active fecal shedding (data not shown). Hence, younger pigs can impose a 
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higher risk for virus spreading, which should be taken into consideration when devising a pig 
flow management strategy and biosecurity measure for PEDV. 
Unlike native pigs, pigs previously exposed to PEDV were protected from subsequent 
challenge of the homologous strain at 2 months after the initial exposure; as neither diarrhea nor 
loose stool was observed in any of the pigs, demonstrating that prior infection can confer 
protective immunity against the disease that may last at least 2 to 3 months based on 
observations in this study. Such clinical protection against homologous viruses has also been 
reported by other investigators (24, 32). While clinical protection was apparent in the re-
inoculated pigs, fecal shedding of the virus was detected by PCR as also shown by others (23, 
24), indicating that these pigs may not have sterile immunity after re-inoculation. These 
observations raise the concern that PEDV introduction in a herd that has previously experienced 
PED may not be recognized readily due to the lack of clinical signs. Introduction of the virus, 
however, can create non-clinical shedders which contribute to further virus spreading unless 
strong sterile immunity is established. It is not known whether anti-PEDV sterile immunity is 
short-lived, or takes a longer time to be established after initial exposure, or requires boost 
immunizations. In our study, the immunity established by prior infection, even though it was not 
the sterile immunity, appears to suppress virus replication in pigs when subsequently challenged 
with the virus. The proportion of fecal shedders within 2-3 dpi was less than 50% in the re-
inoculated pigs as compared to 100% in the first-inoculated naïve pigs (Fig. 1). Furthermore, the 
virus also disappeared more quickly from the re-inoculated pigs. At 21 dpi, there was no pig 
shedding the virus in feces among the re-inoculated group while more than 70% of the first 
inoculated pigs still shed the virus. It is speculated then that prior PEDV infection in our study 
primed pigs immunologically against the virus but may have not established strong immunity. 
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Additional exposure or immunization may be required to establish stronger/sterile immunity 
against PEDV. 
Good mucosal immunity, particularly in the gut, is necessary for pigs to effectively 
control enteric viral pathogens such as PEDV. It is, however, historically hard to measure the 
mucosal immunity although numerous methods have been utilized (33,34). As such, serology has 
been commonly used to assess the immune status and determine exposure or vaccination. 
Traditionally, serology tests have been performed on serum or plasma samples to assess 
antibodies in blood circulation (23, 24, 35). More recently, the utility of swine OF for monitoring 
diseases in a population or herd immune status by detecting antibodies and/or pathogens has 
been demonstrated (28). Our study compared anti-PEDV antibody kinetic profile in sera and oral 
fluids after experimental inoculation and re-inoculation of the virus via the oral route. A few 
things are worthwhile to note. First, oral administration of PEDV induced serum antibody 
response rather quickly (as early as 7 dpi) as determined by IFA test and ELISA (Fig. 2 and Fig. 
3). PEDV-specific antibodies were also detectable in OF as early as 14 dpi by ELISA (Fig. 4), 
which corroborates previous reports (22, 24, 36). These results suggest that serology can be an 
effective tool to identify pigs which have been exposed to PEDV. Second, infected pigs 
developed serum VN antibody which remained at a low titer and almost unchanged in our study 
(Fig. 2), indicating that the predictive value of VN antibody for the protective immunity against 
PEDV in exposed pigs may be limited. It should be noted, though, that other investigators (25, 
27, 37) have reported earlier and higher VN antibody response than ours using different methods 
and different strains of PEDV. Third, IgA was the dominant isotype in both serum and OF since 
its level was higher than IgG at all sampling points (Fig. 3 and Fig. 4), which is partly in 
disagreement with previous reports (23, 33) showing higher IgG in serum than IgA. 
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Interestingly, the kinetics of IgA antibodies between serum and oral fluid significantly differed 
particularly after 21 dpi whereas IgG kinetics in both sera and oral fluids was similar, suggesting 
that OF may contain IgA locally produced or of fecal origin. While serum antibodies (both IgG 
and IgA) and OF IgG continued to decline after 28 dpi, IgA in oral fluids remained high once it 
peaked until re-inoculation (56 dpi). As this study demonstrated that previously exposed pigs 
were clinically protected from the homologous re-challenge (Table 2), detection of IgA in OF 
may provide a better prediction for protective immunity against subsequent challenge. However, 
such utility remains to be further studied. 
Temporal profiling of serum IgG response to each recombinant PEDV structural protein 
showed that all major structural proteins of PEDV were immunogenic except E protein, which 
agrees with previous reports (26, 37-39). Interestingly, the method employed in the study (i.e., 
immunofluorescence microscopy on BHK-21 cells transiently expressed each of the PEDV 
structural proteins) could not detect IgG response to M protein in pigs until after re-inoculation 
(Table 3), whereas other groups reported a good correlation in results between M protein-based 
ELISA results and VN test (37) and detection of anti-M antibody between 10 and 42 dpi by a 
fluorescent microbead-based immunoassay using recombinant M protein. Since IgG response to 
M protein was detected after 14 dpi using Western immunoblotting, which used denatured 
antigen (data not shown), it is suspected that the discrepancy between our study and the others 
may have been attributed to the difference in antigen form in each assay. Based on the intensity 
of the fluorescent signal, the level of IgG antibody to S and N proteins appeared to be higher 
than to M protein in our assessment, which is in agreement with other reports (25, 26). As N 
protein is known to be the most abundant antigen produced throughout PEDV infection (11), it is 
logical to assume that N protein can be a good antigen basis for antibody detection although the 
55 
 
test result may not be indicative of protective immunity. It is also logical to postulate that S 
protein, which is a surface projection of PEDV, is associated with the development of serum VN 
antibody. However, VN antibody could not be detected in oral fluids in our study, and serum IgG 
response to each of PEDV structural proteins may not be directly translated into the viral protein 
reactivity profile of antibodies in oral fluids. As our study suggests that oral fluid IgA may be an 
indicator of protective immunity, further study remains to characterize the temporal viral protein 
reactivity profile of IgA in oral fluids.  
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Table 1. Study design 
   Day post inoculation (dpi) 
Group No. of pig Inoculum† 1 2 3 4 7 14 21 28 35 42 49 56* 63 76 
Challenge 56 PEDV 4§ 4 4 4 4 4 4 4 4 4 4 4 4 4 
Control 42 Sham 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
†Porcine epidemic diarrhea virus (PEDV) US/Iowa/18984/2013 (1 x 103 PFU/ml) was used as virus inoculum while virus-free cell 
culture media was used as sham inoculum. Each inoculum was given via oro-gastric catheter (1ml/pig). 
*Pigs were re-inoculated with PEDV or sham inoculum 
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Table 2. Clinical Outcome of infection and re-infection    
                  
         
1st inoculation (3 weeks of age/0 dpi)  2nd inoculation (11 weeks of age/56 dpi) 
                  
         
No Inoculation (N)   No Inoculation & Challenge (N-N)  
   No Diarrhea       No Diarrhea   
         
     Challenged Group (N- C)  
Challenged Group (C)   
   10-70% of pigs show diarrhea during 3 to 7 dpi, then 
   started to recover 
   25-70 % of pigs show diarrhea from  
   2 to 7 dpi, then started to recover. 
   No Diarrhea after 10 dpi.  
No Challenge Group (C-N)  
   No Diarrhea 
     Re-Challenged group (C-C)  
        No Diarrhea   
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Table 3. Profiles of serum IgG antibody response to structural proteins of porcine epidemic diarrhea virus (PEDV) as determined by 
immunofluorescence microscopy on BHK-21 cells transiently expressing recombinant spike (S), spike subunit 1 (S1), envelope (E), 




Days post inoculation (re-inoculation) 
0 7 14 21 28 35 42 49 56 63 70 76 63(7) 70(14) 76(20) 
S - +* + + + + + + + + + + ++§ ++ ++ 
S1 - + + + + + + + + + + + ++ ++ ++ 
E - - - - - - - - - - - - - - - 
M - - - - - - - - - - - - - + + 
N - + ++ ++ ++ + + + + + + + ++ ++ ++ 
*Positive 




    
 
Figure 1. Fecal shedding of porcine epidemic diarrhea virus (PEDV) from naïve 3-week-old 
(blue bars) and 11-week-old (orange bars) pigs and 11-week-old pigs (yellow bars) exposed to 




























    
 
 
Figure 2. Kinetics of serum antibody responses to porcine epidemic diarrhea virus over time in 
pigs after experimental inoculation (dotted line) or re-inoculation (solid line) as measured by 
indirect fluorescent antibody (IFA) and virus neutralization (VN) assays. The average IFA 
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Figure 3. Isotype profile of serum antibody response to porcine epidemic diarrhea virus (PEDV) 
in pigs after experimental inoculation (dotted line) or re-inoculation (sold line). PEDV-specific 
IgG, IgA, and IgM antibody titers were quantified by ELISA with plates coated with PEDV 
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Figure 4. Detection of anti-porcine epidemic diarrhea virus (PEDV) antibodies, their levels, and 
isotypes in swine oral fluids over time after experimental PEDV inoculation. PEDV-specific IgG 
(blue), IgA (red), and IgM (green) antibody titers were quantified by ELISA with plates coated 
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3.1  Abstract 
Porcine epidemic diarrhea virus (PEDV) is the causative agent of effusive diarrhea in 
pigs of all ages and high mortality in pre-weaning pigs. Although infected pigs typically do not 
have clinical diarrhea after 7 to 10 days post infection, pigs still shed the virus in feces for an 
extended period of time.  The main objective of this study was to determine if the presence of 
PEDV in non-intestinal tissue(s) contributes to such a long fecal shedding of virus following 
infection. Sixty-three, 3-week-old pigs were randomly allocated into control (n=27) and 
challenged (n=36) groups.  Challenged pigs were administered 1 ml of 1x103 PFU/ml of PEDV 
isolate (US/Iowa/18984/2013) by gastric gavage.  Three control and four challenged pigs were 
necropsied on days post inoculation (dpi) 1, 2, 3, 4, 7, and weekly thereafter, until dpi 35.  The 
presence of PEDV in serum and various tissues was investigated using real-time reverse 
transcription-polymerase chain reaction (RT-qPCR), immunohistochemistry (IHC), and 
fluorescent in situ hybridization (FISH).  Serum viremia was observed in all challenged pigs 
beginning at dpi 1 until dpi 3 and then was no longer detectable by PCR after dpi 7.  Viral RNA 
was detected in various tissues (stomach, colon, lung, heart, spleen, kidney, and mesenteric 
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lymph node) in addition to small intestines as early as 1 dpi but was no longer detectable after 14 
dpi except in the mesenteric lymph node (MLN) in which PEDV RNA continued to be detected 
by 28 dpi.  PEDV antigen was also detected in MLN and the virus was isolated from the tissue 
by 14 dpi.  The findings from the study did not support the contribution of virus 
infection/replication in non-intestinal tissues to fecal shedding for the extended period (35 dpi).  
The immunobiological significance of detecting PEDV in the mesenteric lymph node for a 
prolonged time warrants further investigation as it plays a role in local immunity. 
3.2  Introduction 
Porcine epidemic diarrhea (PED) is a serious viral enteric disease of swine causing 
effusive diarrhea in pigs of all ages and has caused significant economic losses in some of swine 
producing countries worldwide due to high mortality in pre-weaning pigs (1-4).  The disease was 
first identified in the United Kingdom in 1971 and has been a great problem in many Asian 
countries (3, 5, 6).  Following its emergence in the US in April 2013 for the first time, PED 
rapidly spread across the country, causing a major economic blow ($300M/year revenue loss) to 
the US swine industry (3, 5, 7).  
Porcine epidemic diarrhea virus (PEDV), the causative agent of PED, is an enveloped, 
single-stranded, positive-sense RNA virus belonging to the order genus Alphacoronavirus in the 
family Coronaviridae along with other swine coronaviruses such as transmissible gastroenteritis 
virus (TGEV) and porcine respiratory coronavirus (8).  The PEDV genome is approximately 28 
kb in length and is comprised of seven open reading frames that encode for four structural 
proteins, namely spike (S), membrane (M), envelope (E) and nucleocapsid (N) (9, 10). 
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PEDV is transmitted via a fecal-oral route and is known to replicate in the mature 
intestinal enterocytes that leads to villous atrophy, thereby causing malabsorptive, watery 
diarrhea with anorexia and occasional vomiting in pigs of all ages (3, 4, 11, 12).  Various studies 
have shown that under experimental conditions, pigs infected with PEDV shed the virus in feces 
for a long period (up to 35 days post-infection) even after clinical diarrhea is ceased by 7-10 dpi 
(13-15).  Although no non-intestinal replication of the virus in infected pigs has been reported 
besides short-term viremia (12-14), it can be speculated that such a long fecal shedding may be 
attributed to viral replication in tissues other than the small intestine.  The following study was 
conducted to determine if the presence of PEDV in non-intestinal tissue(s) contributes to such a 
long fecal shedding of the virus after infection by assessing viremia and distribution of PEDV in 
various tissues using a weaned piglet model. 
3.3  Materials and Methods 
3.3.1  Animal study 
The animal use for the study was approved by the Iowa State University Institutional 
Animal Care and Use Committee (protocol log #6-13-7593-S).  Sixty-three, 3-week-old weaned 
pigs were purchased from a commercial, cross-bred farrow-to-wean farm with no known prior 
exposure to PEDV and transported to the Livestock Infectious Disease Isolation Facility at Iowa 
State University, which is operated at compliance.  Pigs were also free of porcine reproductive 
and respiratory syndrome virus and TGEV.  Acclimation procedure was described elsewhere 
(13).   
Pigs were randomly allocated into sham-inoculated control (n= 27) or challenged (n=36) 
groups.  Groups were housed in the same facility but separated by room and ventilation system.  
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Pigs in each room were confined by pens on a solid floor that was rinsed daily, fed a balanced 
diet ad libitum based on weight, and given free access to water.  PEDV-challenged pigs received 
a 1 ml dose of  1x103 plaque-forming unit (PFU)/ml of the virus via oro-gastric gavage using a 
12-gauge French catheter flushed with 10 ml of 0.01M phosphate-buffered saline (PBS, pH 7.4; 
Sigma-Aldrich, St. Louis, MO) on day 0.  Sham-inoculated pigs (i.e., negative controls) were 
administered with volume matched virus-free cell culture media in the same manner described 
above.  Three control and four challenged pigs were randomly selected for necropsy on 1, 2, 3, 4, 
5, 7, 10, 14, 21, 28, and 35 days post inoculation (dpi).  Blood samples were collected from these 
pigs before euthanasia on each necropsy day.  Fresh and formalin fixed sample collection at 
necropsy included: small intestine, colon, mesenteric lymph node, tonsil, stomach, lung, heart, 
liver, spleen, and kidney.  Serum was also collected using vacutainers from all remaining pigs 
after each necropsy on dpi 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, and 35. Fecal swabs were collected 
prior to inoculation (dpi 0), daily for the first week after inoculation, dpi 10, 14, 17, 21, 24, 28, 
31, and 35 from all pigs before necropsy.  
3.3.2  Virus inoculum 
A plaque-cloned isolate of PEDV designated as US/Iowa/18984/2013 (GenBank 
accession #KF804028) (16) was propagated in Vero cells (ATCC® CCL-81, Manassas, VA) as 
previously described (6, 17) and used to inoculate pigs.  The viral inoculum represented 6 cell-
culture passages. 
3.3.3  Polymerase chain reaction (PCR) assay  
A real-time reverse transcription-polymerase chain reaction (RT-qPCR) assay targeting a 
conserved region of the PEDV nucleoprotein (N) gene was performed as previously described (6, 
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13) with minor modifications to include viral standards with known infectious PEDV titers for 
quantification.  In brief, viral RNA was extracted from samples using the Ambion® MagMAX ™ 
viral RNA isolation kit (Life Technologies, Carlsbad, CA) and a KingFisher® 96 magnetic 
particle processor (Thermo-Fisher Scientific, Waltham, MA) as per manufacturers’ 
recommended protocols.  Five µl of each template was used in PCR set-up for a 25µl total 
reaction using the Path-ID® Multiplex One-Step RT-PCR kit (Life Technologies, Carlsbad, CA).  
Primers and probe (IDT, Coralville, IA) were:  
 Forward primer: 5’-CGCAAAGACTGAACCCACTAACCT-3’;  
 Reverse primer: 5’-TTGCCTCTGTTGTTACTTGGAGAT-3’; and  
 Probe: 5’-FAM-TGTTGCCAT/ZEN/TACCACGACTCCTGC-Iowa Black-3’.  
The RT-qPCR was run using an Applied Biosystem® 7500 Fast Real-time System (Life 
Technologies) as follows: 48° C for 10 minutes, 95° C for 10 minutes, and 45 cycles of 95° C for 
15 seconds followed by 60° C for 45 seconds.  Results analysis included a threshold at 0.1 and 
the automatic baseline setting.  Cycle threshold (Ct) values were recorded through cycle 40.  
Each Ct value was then converted to viral titer (PFU equivalent/ml) estimated from a standard 
curve generated with the viral standards mentioned above.  A set of viral standards were included 
in each PCR plate. 
3.3.4  Immunohistochemistry 
Tissues samples were collected in 10% neutral buffered formalin, allowed to fix for 48 
hr, and then transferred to 100% alcohol before trimming, routine processing, and paraffin 
embedding for standard hematoxylin and eosin slide preparation at the Iowa State University 
Veterinary Diagnostic Laboratory (ISUVDL) using an established protocol.  
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Immunohistochemistry (IHC) was also performed at the ISUVDL.  IHC slides were prepared for 
all the enteric and non-enteric tissues from all challenged pigs. Antigen detection and scoring 
were performed as described previously (13). 
Dual staining for macrophages and PEDV was also performed as described previously 
(18).  Formalin-fixed and paraffin wax-embedded tissue sections of all selected samples were 
used for Iba1 (macrophage marker) and PEDV IHC.  The slides were dewaxed and hydrated, 
followed by antigen retrieval using pretreatment reagent (DIVA, BioCare Medical, Concord, 
CA).  The slides were then pretreated with a blocking buffer containing 10% normal goat serum 
(NGS) (Thermo Scientific, Fremont, CA) for 30 min and incubated with the primary antibody 
(anti-Iba1, Wako, Richmond, VA) for 1 hr.  The primary antibody was followed by incubation 
with the Alkaline Phosphatase (Thermo Scientific, Waltham, MA) tagged secondary antibody for 
1 hr.  A chromogen complex containing Vector® Blue Alkaline Phosphatase (Blue AP) 
Substrate (Vector Laboratories, Burlingame, CA) was used to visualize targeted antigen.  The 
slides were again blocked with 10% NGS for 30 min and staining procedure was followed for 
PEDV as described previously (13).  
3.3.5  Fluorescent in situ hybridization  
Fluorescent in situ hybridization (FISH) was performed on paraffin-embedded tissue 
sections (4 µm thick) prepared as described above using an oligonucleotide probe targeting the N 
gene of PEDV (5’-TGTTGCCATTACCACGACTCCTGC-3’).  The oligonucleotide probe was 
obtained from a commercial vendor (Invitrogen Custom Oligos, Life Technologies, Carlsbad, 
CA) with a 5’ label of orange fluorescent dye (Alexa Fluor™ 555, Life Technologies, Carlsbad, 
CA) and was reconstituted in a commercial hybridization buffer (Bond™ Hybridization Solution, 
Leica Biosystems, Newcastle Upon Tyne, UK) immediately prior to use (5 ng/µl).   
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The procedure was performed using a commercially available system (Leica Bond-III, 
Leica Biosystems, Melbourne, Australia) as follows:  1) sections were dewaxed using a 
commercial dewaxing solution (Bond™ Dewax Solution, Leica Biosystems, Newcastle Upon 
Tyne, UK) and alcohol per the manufacturer’s directions; 2) sections were then treated with a 
commercially available enzyme pretreatment kit (Bond™ Enzyme Pretreatment Kit, Leica 
Biosystems, Newcastle Upon Tyne, UK) for 5 min followed by 5 rinses with a commercial wash 
solution (Bond™ Wash Solution, Leica Biosystems, Newcastle Upon Tyne, UK); 3) the diluted 
probe was applied and allowed to hybridize at 45° C for 12 hr; and 4) sections were rinsed, 
cover-slipped in aqueous mounting media, and immediately examined with a fluorescent 
microscope with a filter appropriate for the fluorescent dye.  Fluorescent image analysis was 
performed to determine positive or negative signal as previously described (19). 
3.3.6  Virus isolation  
Selected tissues from PEDV-positive and negative pigs were used to generate a 10% 
(wt/vol) homogenate in Earle’s balanced salt solution (Sigma-Aldrich, St. Louis, MO).  The 
homogenate suspension was centrifuged at 4,000 x g for 10 minutes at 4° C for clarification and 
the resulting supernatant was used for virus isolation (VI).  Each tissue homogenate supernatant 
was diluted 1:5 in Dulbecco Modified Eagle Medium (DMEM, ThermoFisher Scientific, 
Waltham, MA) containing 10 µg/ml of trypsin (hereafter, infection media) and added to Vero 
cell monolayers prepared in 96-well plates prepared 24 hours before.  After 1hr incubation at 37° 
C (adsorption), cells were washed twice with the infection media and then further incubated in 
the same infection media at 37° C for 48 hr with daily monitoring for cytopathic effect (CPE). 
Regardless of CPE observation, cells were fixed with cold 80% aqueous acetone solution, air 
dried for 30 minutes, and subjected to an immunofluorescence assay.  The fixed cell monolayers 
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were incubated with anti-PEDV mouse monoclonal antibody 6C8 (BioNote, Hwaseong-si, 
Gyeonggi-do, Korea) for 45 minutes at room temperature and unbound antibodies were removed 
by washing cells with 0.01M PBS, 7.4 pH (ThermoFisher Scientific, Waltham, MA).  The cells 
were then stained with FITC-conjugated goat anti-mouse IgG (Kirkegaard & Perry Laboratories, 
Gaithersburg, MD) for 45 minutes followed by washing with PBS and observed under a 
fluorescence microscope.  The positively stained cells exhibited cytoplasmic green fluorescence 
indicating viral growth in the cell culture.  The presence of PEDV in each cell culture fluid was 
also confirmed by RT-qPCR. 
3.4  Results 
3.4.1  Clinical outcomes and viral shedding 
 Control pigs showed no signs of diarrhea and fecal shedding for the duration of the study. 
PEDV challenged pigs displayed diarrhea starting at dpi 2 and recovering by dpi 10 along with 
subsided clinical signs.  However, pigs continued to shed virus until dpi 24 regardless of the 
clinical signs.  The details of clinical assessment have been described in the previous publication 
from our lab (13). 
3.4.2  Viremia 
Serum viremia pattern in challenged pigs by dpi is summarized in Table 1.  No PEDV 
RNA was detected in sera from any of the control pigs for the duration of the study.  In contrast, 
PEDV RNA was detected in 50% (2 of 4) of the challenged pig’s serum samples on dpi 1 with a 
viral titer (PFU equivalent/ml) of 16.7 and 36.9, respectively.  About 25% (1 out of 4) of 
challenged pigs tested positive for PEDV RNA on dpi 2, 3, and 4 and 21% (4 out of 19) on dpi 5. 
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Thereafter, the proportion of viremic pigs gradually diminished until dpi 14 with a very low viral 
titer. 
3.4.3  PEDV detection in tissues 
A higher level (up to 12 PFU equivalent/ml) of PEDV RNA was detected in small 
intestinal tissues (duodenum, jejunum, ileum) until dpi 24, which has been described in detail in 
a previous report from our laboratory (13).  PEDV RNA was also detected virtually in all other 
tissues collected from infected pigs at varying levels and for varying durations after inoculation 
as summarized in Table 2.  In addition to the small intestine, PEDV RNA was detected 100% of 
tissues from the stomach, colon, mesenteric lymph nodes (MLN) and kidney collected at one or 
more necropsy days after inoculation.  Overall, a higher percentage of MLN were PCR-positive 
for PEDV than any other tissues tested.  No viral RNA was detected in any of the tissues 
collected from the sham-control pigs. 
In the small intestine, PEDV antigen was detected in villus enterocytes (Fig. 1) until dpi 
14 and was not detectable after that (13).  Even though many other tissues from inoculated pigs 
were positive for PEDV RNA at some points in time after inoculation, PEDV antigen was 
detected by IHC only in MLN (Fig. 2) and colonic epithelium (Figure 3).  Based on the 
subjective reading of IHC slides, PEDV antigen was more abundant in MLN than the colon.  
Nonetheless, the staining intensity diminished in later time points as compared to the earlier time 
points for both colon and MLN. 
Since most of the tissues examined were negative for PEDV antigen by IHC, all tissues 
were further tested with FISH.  The presence of PEDV RNA could not be demonstrated in any of 
the tissues including MLN.  In contrast, the nucleic acid of PEDV was detectable by FISH in 
76 
 
    
small intestinal tissues from the experimentally challenged pigs (Fig. 4).  Until dpi 7, the 
distribution of viral nucleic acid in the intestinal tissues was wide, and strong hybridization 
signals were observed.  Fewer positive cells with fading hybridization signal were observed at 
dpi 14, and the positive signal was no longer detected in the subsequent necropsy points.  
3.4.4  Characterization of PEDV in mesenteric lymph nodes 
As detection of PEDV in MLN was an unexpected observation, location of the virus in 
MLN was investigated using macrophage/PEDV dual staining to rule out passive transfer of the 
virus into MLN.  The presence of PEDV antigen was visualized in both the inside and outside of 
macrophages, demonstrating PEDV in non-macrophage cells (Fig. 5).  
Subsequently, virus isolation was attempted on 11 MLN samples positive for PEDV by 
PCR and IHC to confirm the presence and absence of viable PEDV.  The virus was isolated from 
7 MLN samples (73% recovery rate), suggesting the presence of viable PEDV replicating in 
MLN. 
3.5  Discussion 
Although PEDV-infected pigs typically do not have clinical diarrhea after 7 to 10 days 
post-infection, the pigs still can shed the virus in feces for an extended period (dpi 24) after being 
no longer diarrheic clinically (13).  The objective of this study was to evaluate if the presence of 
PEDV in non-intestinal tissue(s) contributes to long fecal shedding of the virus following 
infection by assessing the distribution of PEDV in various tissues of pigs following experimental 
inoculation.   
Viremia was observed only in the early stages of infection (Table 1) along with severe 
diarrhea and fecal viral shedding at high titers.  Similar findings of viremia and virus fecal 
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shedding have been observed in recent other PEDV studies (12, 14).  Studies with other swine 
enteric coronaviruses, such as TGEV and PDCoV, have also shown early viremia in infected 
pigs via detection of viral RNA (4, 20).  No study, however, has demonstrated the presence of 
the infectious virus in serum.  Although PEDV appears to leave the intestinal tract because it was 
detected in serum, it occurred only in the early stage of infection when the virus entered the 
bloodstream.  At the same time, the viral RNA was also detected in a variety of tissues during the 
early stage. (Table 2).  Therefore, viremia, which is suspected to be due to severe atrophic 
enteritis and alteration in the tight junction in affected intestinal tissues, may account for wide 
tissue distribution of PEDV in infected pigs in early post-inoculation.   
Although PEDV was detected by PCR in various non-intestinal tissues of infected pigs, 
the contribution of the virus in these tissues to fecal shedding for an extended period after 
infection is in question with a few reasons.  First, the level of PEDV RNA in these tissues was 
lower than the level of PEDV RNA in the small intestine.  Second, PEDV RNA was no longer 
detectable in these tissues after 14 dpi while the viral RNA continued to be detected in the small 
intestine until 28 dpi and in feces until 35 dpi.  Third, none of the PCR-positive non-intestinal 
tissues was positive for PEDV antigen as determined by IHC whereas PEDV antigen was 
detectable in the small intestine until 14 dpi (13).  While this is not an unexpected observation 
since IHC for PEDV has been shown to be less sensitive than PCR, (13), no positive signal for 
PEDV RNA was observed in these tissues by FISH either.  In contrast, the strong FISH signal 
was observed in the small intestine of infected pigs (Fig. 4).  As FISH was designed to detect 
intracellular PEDV RNA within a tissue, such negative results suggest that there was no viral 
replication in those PCR-positive non-intestinal tissues.  The positive PCR results may have been 
due to passing-by of PEDV via blood circulation or lymphatics.  Collectively, it is logical to 
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conclude that longer fecal shedding of PEDV should be attributed to viral replication in the small 
intestine. 
In comparison to various tissues positive for PEDV RNA, a higher level of viral RNA 
was detected in the colon and MLN.  Similar findings were reported previously with PEDV 
strain CV777 (21).  The presence of PEDV in these tissues, particularly MLN, is unique as 
compared to other enteric coronaviruses such as TGEV and PDCoV (4, 22).  It is interesting to 
further investigate whether the MLN and/or colonic infection contributes to the severity of PED 
as compared to PDCoV infection or TGE.  Since finding PEDV in the MLN was a rather 
unexpected observation, the question was raised as to its origin or source.  It can be hypothesized 
that the virus may be carried into the MLN by macrophages which phagocytosed the virus in the 
region.  However, this hypothesis is unlikely because: a) dual immunostaining of MLN for 
macrophages and PEDV demonstrated the presence of the virus inside and outside of the cells 
(Fig 5); b) replication of coronaviruses, such as feline infectious peritonitis coronavirus (23) and 
PEDV (24), in macrophage-lineage cells has been reported; and c) virus isolation attempts 
revealed that MLN tissues harbored infectious viruses.  All of these observations suggest that 
PEDV replicates in the MLN once it enters into it passively or actively.  While it is unlikely that 
MLN plays a role in supplying the virus to fecal shedding since lymphoid tissues function as a 
drainage system into lymphatics (25), the immunobiological significance of PEDV replication in 
MLN for a prolonged time warrants further investigation since this organ functions in local 
immunity. 
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Table 1. Serum viremia pattern in the experimentally infected pigs as determined by real-time 
reverse transcription-polymerase chain reaction (RT-PCR)  
DPI N # Positive % Positiveα Min PCR Ct§ Max PCR Ct Mean PFU¥ 
1 4 2 50 27.1 28.9 26.9 
2 4 1 25 36.1 36.2 0.6 
3 4 1 25 32.9 32.9 2.7 
4 4 1 25 37.8 37.8 0.3 
5 19 4 21 32.1 38.7 0.1 
7 18 1 4 37.4 37.4 0.1 
10 15 0 0 >45.0 >45.0 0 
14 15 2 13 32.6 36.6 0.1 
21 9 0 0 >45.0 >45.0 >45.0 
28 8 0 0 >45.0 >45.0 >45.0 
35 4 0 0 >45.0 >45.0 >45.0 
α Proportion of serum PCR-positive pigs for a particular day post inoculation (DPI) 
§Ct: cycle threshold   




    
Table 2. Detection of porcine epidemic diarrhea virus RNA in intestinal and non-intestinal 
tissues 
Samples Percentage positive at given days post inoculation 
 0 1 7 14 21 28 35 
Small Intestine 0 100 100 100 75 50 0 
Stomach 0 100 100 75 0 0 0 
Colon 0 100 100 50 0 0 0 
MLN* 0 75 100 100 100 50 0 
Heart 0 50 75 50 0 0 0 
Lung 0 75 75 0 0 0 0 
Kidney 0 100 75 25 0 0 0 
Spleen 0 75 75 25 0 0 0 
*MLN: Mesenteric Lymph Nodes
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Figure 1. Pig small intestine. Histologic section of intestinal mucosa from a pig infected with 
porcine epidemic diarrhea virus (PEDV) revealing intense immunolabeling (brown color) within 





    
 
Figure 2. Pig mesenteric lymph node. Serial section of MLN revealing intense immunolabeling 
(brown color) of the villous tip at three days post inoculation. Immunohistochemistry for porcine 





    
 
Figure 3. Pig Colon. Serial section of colon revealing intense immunolabeling (brown color) of 
the villous tip at three days post inoculation. Immunohistochemistry for porcine epidemic 





    
 
Figure 4. Pig small intestine. Histologic section of intestinal mucosa from a pig infected with 
porcine epidemic diarrhea virus (PEDV) revealing strong hybridization signal labeling PEDV 
within enterocytes. Fluorescent in situ hybridization using an orange fluorescent probe (Alexa 






    
 
Figure 5. Pig mesenteric lymph node (MLN). Histologic section of MLN from a pig infected 
with porcine epidemic diarrhea virus (PEDV) revealing dual staining of macrophage (blue) and 
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4.1  Abstract 
 
Porcine epidemic diarrhea (PED), caused by PED virus (PEDV), is a devastating enteric 
disease of swine. Spike (S) protein of coronavirus is known to play a critical role in virus 
attachment and entry and is the major target of neutralizing antibodies. However, there is a 
dearth of knowledge on neutralizing epitopes in S protein and the mechanism by which antibody 
interferes with the viral infection. Moreover, the receptor-binding domain (RBD) of PEDV has 
not been determined, which was the subject of the present study. Using bioinformatics tools, the 
putative RBD of PEDV was identified. A recombinant protein was generated from that region, 
and polyclonal and monoclonal antibodies were produced against the protein. The putative RBD 
protein was recognized by swine sera from pigs experimentally infected with PEDV through 
immunofluorescence assay as well as ELISA in a dose-response manner. Antibodies produced 
against the putative RBD protein neutralized PEDV infection to Vero cells. Furthermore, the 
putative RBD protein bound to the surface of the permissive cell (Vero) without aminopeptidase 
N (APN) but not to the non-permissive cell (ST) with APN. Collectively, the putative RBD 
identified in the study appears to be a receptor-binding domain of PEDV which may bind to a 
90 
 
    
cellular receptor other than APN, a known cellular receptor for alphacoronaviruses. As the 
presence of neutralizing epitope(s) in the protein was demonstrated, the protein or corresponding 
region may be used as vaccine antigen (or target) and/or antigen basis for serodiagnosis. 
4.2  Introduction 
Porcine epidemic diarrhea (PED) is an economically significant enteric disease of swine 
affecting pigs of all ages and causing a high rate of mortality (up to 100% in naïve herds) in 
young piglets (1-3). The disease, named “epidemic viral diarrhea” at that time, was first 
identified in the UK in 1971 and then in other European countries and has been a significant 
problem in many pig producing countries in Asia. (4-7). In the US, PED emerged in 2013 for the 
first time, resulting in huge economic losses to the US swine industry (2). Clinically, the disease 
is manifested by anorexia, lethargy, acute severe watery diarrhea, occasional vomiting, and 
dehydration followed by mortality in suckling piglets (8, 9). The causative agent is transmitted 
via the fecal-to-oral route and mainly replicates in the intestinal epithelium (mature enterocytes) 
causing villous atrophy and breakage of gut barrier leading to malabsorptive diarrhea (9-11). 
Vaccination to elicit neutralizing antibodies against PEDV has been considered to be the key for 
the prevention and control of PED (12-14). Despite tremendous efforts, vaccines and vaccination 
strategies have thus far not been efficient to control the disease globally (7). 
Porcine epidemic diarrhea virus (PEDV) is an enveloped, single-stranded, positive-sense 
RNA virus which belongs to the genus Alphacoronavirus in the family Coronaviridae along with 
other swine coronaviruses such as transmissible gastroenteritis virus (TGEV) and porcine 
respiratory coronavirus (PRCV) (15). The genome of PEDV is approximately 28 kb in length, 
which comprises seven open reading frames (ORFs) including ORF1ab and ORFs 2-6. The first 
two-thirds of the genome (ORF1) encodes for a large viral polyprotein which is cleaved by viral 
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proteases into 16 nonstructural proteins including polymerase. The remaining one-third of the 
genome (ORFs 2-6) encodes four structural proteins named spike (S) protein, membrane (M), 
envelope (E) and nucleocapsid (N) and one accessory protein ORF3 (7, 16, 17).   
Coronaviruses (CoVs) have surface projections consisting of homotrimers of 
glycosylated S protein which is a type I membrane protein (18). The S protein of CoV is known 
to play a pivotal role in virus entry to target cells and is the key determinant of tissue tropism (5, 
17). Immunologically, the protein is usually the target of virus-specific neutralizing antibodies 
(19). Similar to other CoVs, cellular attachment and entry of PEDV into host cells are postulated 
to be mediated by its S protein which is exposed on the virion surface (20, 21). PEDV S protein 
is also believed to contain neutralizing epitopes whose locations have been predicted as follows: 
residues 201-212, 499-638, 636-789, 744-759, 756-771, and 1368-1374 (22-29). Several groups 
have shown that vaccination of pigs with a full or truncated form of S protein provides protective 
immunity against infection to some extent and elicits an anti-viral neutralizing antibody response 
(26, 27, 30). 
PEDV S protein contains roughly 1386 amino acid (aa) residues (24). Similar to S 
proteins of other CoVs, PEDV S protein consists of an N-terminal signal peptide, a large 
extracellular region, a single transmembrane domain, and a short cytoplasmic tail (24). The 
protein can be functionally divided into S1 (1-729 aa) and S2 (730-1386 aa) domains as is the 
case for other CoVs (24). The S1 region is highly variable and is involved in virus attachment to 
cell surface receptor (31). On the other hand, the S2 region is highly conserved and is involved in 
virus and host cell membrane fusion (24, 31). A recent study with small overlapping S protein 
fragments of PEDV has shown several neutralizing epitopes in both regions (31, 32).  
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PEDV S1 encompasses a signal peptide (residues 1-18), N terminal domain (NTD; 
residues 19-233) which exhibits sialic acid binding activity, and C-terminal domain (CTD; 
residues 477-629) which may interact with cellular receptors (24). Even though the S1 domain of 
CoV’s S protein has been shown to contain the receptor-binding domain (RBD), there is 
considerable variability in its location within the S1 domain among CoVs (20, 21, 33). Two 
swine alphacoronaviruses (TGEV and PRCV) are known to use porcine aminopeptidase N 
(pAPN), also known as porcine CD13, for the attachment leading to cell entry (34). The APN-
binding domains of TGEV, PRCV, and other Alphacoronavirus have been identified at the C-
terminal portion of the S1 region of S protein (20, 35, 36). For PEDV, CD13 has also been also 
believed to be the functional cellular receptor (37, 38). However, its role as a receptor for PEDV 
has been controversial and recently disputed (39). Recently, it has been reported that CD13 
rather promotes virus infectivity by its APN activity (39, 40). In vitro, PEDV replicates only in 
Vero cells which lack CD13 but are permissive to PEDV in the presence of trypsin (9, 41). Vero 
cells are, however, not permissive to TGEV even with trypsin treatment. Similarly, swine 
testicular (ST) cells, which have CD13, are known to be permissive to TGEV regardless of 
trypsin treatment but not to PEDV even with trypsin treatment (42, 43). Our objective was to 
identify PEDV RBD and characterize its role in cell binding, viral infection, and 
immunogenicity.  
4.3  Materials and Methods 
4.3.1  Cells and viruses 
US PEDV isolate US/Iowa/18984/2013 (GenBank accession #KF804028) was 
propagated in Vero cells (ATCC® CCL-81; ATCC, Manassas, VA), an African Green monkey 
kidney cell line, as previously described (9, 41, 44). Briefly, Vero cells were cultured and 
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maintained in Dulbecco Modified Eagle’s Medium (DMEM, ThermoFisher Scientific, Waltham, 
MA) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Flowery Branch, 
GA), 100 unit/ml penicillin (Thermofisher Scientific, Waltham, MA), 100 µg/ml streptomycin 
(ThermoFisher Scientific, Waltham, MA), 0.3% tryptose phosphate broth (ThermoFisher 
Scientific, Waltham, MA), and 0.02% yeast extract (Sigma, St. Louis, MO). For virus 
propagation, PEDV was propagated in Vero cells in the infection media which was DMEM 
supplemented with 0.3% tryptose phosphate broth, 0.02% yeast extract, 100 unit/ml penicillin, 
100 µg/ml streptomycin and 10 µg/ml trypsin 250 (Gibco, Waltham, MA). 
BHK-21 cells (ATCC® CCL-10™), a baby hamster kidney cell line, were cultured in 
Minimum Essential Medium (MEM) with Earle’s balanced salts (Sigma-Aldrich, St. Louis, MO) 
supplemented with 10% FBS at 37°C with 5% CO2 supply. Swine testicular (ST) cells (ATCC® 
CRL-1746™) were cultured in Eagle’s MEM (ATCC) with 10% FBS.   
4.3.2  Multiple sequence alignment and phylogenetic analysis 
Sequences of S protein for PEDV and other alphacoronaviruses were obtained from 
GenBank® for comparison. Protein sequences included in the analyses were KF804028.1 
(PEDV), Q0PKZ5 (TGEV), AAA46905.1 (PRCV), Q65984 (canine CoV), P10033 (feline CoV), 
P15423 (human CoV-229), Q6Q1S2 (human CoV-NL63), and Q9Q9P1 (infectious bronchitis 
virus). Based on known RBDs of alphacoronaviruses, those sequences were compared with S 
protein sequences of various PEDV strains to identify a potential RBD of PEDV. The sequence 
alignment was carried out with the T-Coffee program (EMBL-EBI, http://www.ebi.ac.uk/). 
Phylogenetic analysis of S proteins was done using MEGA 6 (45). Multiple sequence alignments 




    
 
4.3.3  Tertiary structure prediction and structural model evaluation 
The structural model of the putative PEDV RBD was predicted using I-TASSER 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/) (46). Several models suggested from I-
TASSER based on sequence input were downloaded in protein data bank (PDB) format and 
evaluated for the accuracy of prediction. Images of RBD molecular structures were generated 
using PyMol. Molprobity (http://molprobity.biochem.duke.edu/) was used independently of 
server scores to evaluate the quality of tertiary models. Molprobity evaluated all atom clash 
scores, Ramachandran outliers, and bond angles to generate a mean Molprobity score based on 
weighted averages of included factors (47, 48).  
4.3.4  Cloning and immunofluorescence screening 
For initial screening of expression, the selected putative RBD gene fragment was 
constructed to have a Flag (DYKDDDDK) tag at the 3’end and PEDV signal peptide (49) at 
5’end. The gene fragment was purchased from Integrated DNA Technologies, Inc. (Coralville, 
IA). Cloning was performed in a mammalian expression vector, pCI-neo (Promega, Madison, 
WI) as per the manufacturer’s recommended protocol and subsequently transformed in E. coli 
DH5α. Plasmid DNA was isolated using the PureLink™ Quick Plasmid Miniprep kit (Invitrogen, 
Carlsbad, CA). Gene sequences were confirmed by Sanger sequencing which was done at the 
Iowa State University Nucleic Acid Facility.  
When the BHK-21 cells were 70-80 % confluent, transfection was done using TransIT®-
LTI (Mirus Bio LLC, Madison, WI). After 24 hr of transfection, the monolayer was fixed with 
4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO) and permeabilized using 0.2% Triton-X 
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100 (Sigma-Aldrich, St. Louis, MO) before an immunofluorescence assay was performed. PEDV 
hyperimmune swine serum generated in our lab (10) and FITC-labelled goat anti-swine IgG 
(H+L) (Seracare Life Sciences Inc, Milford, MA) was used as the primary and secondary 
antibody, respectively, to visualize the presence of the putative RBD protein expressed in the 
transfected cells. For the Flag detection, anti-FLAG® murine monoclonal antibody (Sigma-
Aldrich, St. Louis, MO) and donkey anti-mouse IgG (H+L) labeled with Alexa 594 (Invitrogen, 
Carlsbad, CA) was used. The stained cells were observed under a fluorescence microscope. 
4.3.5  Preparation of recombinant putative PEDV RBD protein 
The nucleotide sequence corresponding to the putative PEDV RBD protein of 148 aa 
(PEDV S protein residues 494-641) was cloned into the EcoRI and HindIII sites of pGen2 vector 
(Dr. Adam Barb, Iowa State University, Ames, IA) with N-terminal His8 and GFP tags and a 
tobacco etch virus (TEV) protease digestion site as described previously with modifications (50, 
51). RBD gene sequence of PEDV was assembled as a C-terminal fusion to an N-terminal signal 
sequence, 8xHis tag, AviTag, GFP, and TEV protease recognition sequence in a custom 
mammalian expression vector driven by the CMV promoter (pGEn2).  
FreeStyle™  293-F  Cells grown in FreeStyle™ 293 Expression Medium (Life 
Technologies, Carlsbad, CA) on a shaker set at 125 RPM with 8% CO2 and 80% humidity at 
37°C were transfected at a density of 3×106 live cells per ml with 3 µg/ml of PEDV RBD-pGEn2 
expression vector DNA and 9.0 µg/ml polyethyleneimine (PEI) (Sigma Aldrich, St. Louis, MO) 
(50).  Cells were diluted 1:1 after 24-hr incubation with FreeStyle™ 293 Expression Medium 
supplemented with 4.4 mM valproic acid (Sigma-Aldrich, St. Louis, MO). Transfected cells 
were harvested after 6 days, and the medium was clarified by centrifugation at 1000 x g for 5 
min. The supernatant with expressed protein was centrifuged at a high speed (14,000 x g for 10 
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min) to remove any remaining cell debris. The recombinant putative RBD protein was purified 
using a Ni-NTA Superflow (QIAGEN, Hilden, Germany) as per the manufacturer’s 
recommended protocol (50). The medium was adjusted to contain 30 mM imidazole and loaded 
onto a column containing 5 ml Ni-NTA Superflow equilibrated with 20 mM of buffer A (pH 8.1) 
containing Tris-HCl, 500 mM NaCl, and 30 mM imidazole. Following the loading of the cell 
culture supernatant, the column was washed with 75 ml buffer A and eluted with 25 ml same 
buffer A but containing 250 mM imidazole. The eluted fluorescence protein was then 
immediately exchanged with 25 mM MOPS (pH 7.2, 0.1M sodium chloride) using Amicon® 
Ultra 15-mL centrifugal filters and a 10-kDa molecular weight cutoff (MilliporeSigma, 
Burlington, MA). Histidine and GFP tags were removed from the fused protein using AcTEV™ 
Protease A (Invitrogen, Carlsbad, CA) as per the manufacturer’s recommended protocol (50). 
4.3.6  Generation of polyclonal antibody specific for PEDV RBD 
Two New Zealand white rabbits (Charles River Laboratories, Wilmington, MA) were 
immunized intradermally with 100 µg of the purified recombinant RBD protein without any tags 
emulsified with Freund’s incomplete adjuvant (Sigma-Aldrich, St. Louis, MO) and boosted four 
times with a freshly prepared emulsion of 100 µg of the recombinant RBD protein in Freund’s 
incomplete adjuvant at 2-week intervals. The immunization was performed at the Iowa State 
University Hybridoma Facility. Sera were collected before immunization and at each time of 
boost injection. All sera were tested by an enzyme-linked immunoassay (ELISA) using the 
purified recombinant RBD protein (hereafter, RBD-ELISA) and indirect immunofluorescence 
assay (IIFA) using PEDV-infected Vero cells (hereafter, PEDV-IIFA) as described below to 
determine the presence or absence of antibodies reactive to the recombinant RBD and/or PEDV. 
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The serum samples were also evaluated for neutralizing activity against PEDV using virus 
neutralization (VN) assay as described below.  
4.3.7  Generation of RBD-specific monoclonal antibodies 
Putative PEDV RBD-specific monoclonal antibodies (mAbs) were produced at the Iowa 
State University Hybridoma Facility. Briefly, two SAS Sprague Dawley rats (Charles River 
Laboratories, Wilmington, MA) were immunized subcutaneously with the purified recombinant 
RBD protein (50 µg/rat) adjuvanted with Alhydrogel® adjuvant 2% (InvivoGen, San Diego, CA) 
three times at 3-week intervals. The rats were sacrificed 10 days after the last boost 
immunization and spleens were collected from the rats. Rat splenocytes were fused with rat 
myeloma cells (ATCC, Manassas, VA) and cultured at 37°C with 5% CO2 supply and 80% 
humidity in the presence of hypoxanthine-aminopterin-thymidine (HAT) medium (ThermoFisher 
Scientific, Waltham, MA) for selection of hybridoma cells following standard protocols. After 
10–14 days of culture, hybridoma cell culture supernatants were screened for the presence of 
RBD- and/or PEDV-specific antibodies by RBD-ELISA and PEDV-IIFA as described below. 
Hybridomas with positive results on their supernatants by both assays were expanded and 
subcloned to generate stable hybridoma cell lines producing mAbs specific for the putative RBD 
protein. Culture supernatants of selected hybridomas were tested for neutralizing activity against 
PEDV using the VN assay as described below. The reactivity of the selected mAbs with the 
putative PEDV RBD was re-confirmed using Western immunoblotting as described below. 
4.3.8  RBD-ELISA 
Each well in 96-well plates (Nunc, ThermoFisher Scientific, Waltham, MA) contained 
100 ng of the RBD protein diluted in coating buffer (BupH™ Phosphate-Buffered Saline Packs, 
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ThermoFisher Scientific, Waltham, MA) and incubated overnight at 4°C. After 5 washes with 
0.01M phosphate-buffered saline (PBS, Gibco, Waltham, MA), pH 7.4, containing 0.05% Tween 
20 (PBST), the unoccupied site in the plates were blocked with 300 µl per well of 1% bovine 
serum albumin (BSA) (Jackson Immuno Research Inc., West Grove, PA) for 2 hr at room 
temperature. The plates were then dried at 37°C for 4 hr and stored at 4°C in a sealed bag with 
desiccant packs until used.  
For testing, samples were first diluted in PBST with 1% BSA using a 2-fold serial 
dilution technique. One hundred µl of each diluted sample was added to the ELISA plates 
(antigen well and control well per sample) and incubated for 1 hr. Unbound antibodies were 
washed off with PBST (5 times) followed by incubation with optimally diluted HRP-conjugated 
anti-rabbit or anti-rat IgG or IgA (H+L) antibodies (Kirkegaard & Perry Laboratories, 
Gaithersburg, MA) for 1 hr. The presence of antigen-antibody complexes was visualized by 
adding TMB substrate (KPL) for 5 min. The colorimetric reaction was then stopped by adding 
100 µL of 1M sulfuric acid to each well. All procedures were performed at ambient temperature. 
Optical density (OD) was measured at 450 nm wavelength using an ELISA plate reader. OD 
values of each test and control samples from antigen wells were normalized by subtracting the 
OD value of uncoated wells. Positive controls (anti-PEDV swine serum, hyperimmune anti-RBD 
rabbit serum), negative controls (pre-immunization sera), and blanks (sterile water) were tested 
in duplicate on each ELISA plate. Net OD from negative controls + 3 standard deviations was 
used as the cut-off for positive.  
4.3.9  Indirect immunofluorescence assay 
IIFA was used to screen supernatants of hybridoma cells and rabbit polyclonal sera 
(pAbs) for the presence of antibody reactive to PEDV or to determine the viral protein specificity 
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of selected mAbs. For PEDV-IIFA, monolayers of Vero cells infected with PEDV were prepared 
in microtitration plates (10) and were incubated with each sample for 1 hr at 37°C. Unbound 
materials were removed by washing each well with 0.01M PBS (Gibco), pH 7.4, 3 times. The 
presence of PEDV-specific antibody was visualized by adding goat anti-rat IgG+IgM+IgA 
(H+L) conjugated with fluorescein isothiocyanate (Bethyl Laboratories, Inc., Montgomery, TX) 
or goat anti-rabbit IgG (H+L) conjugated with Alexa Fluor 594 (Invitrogen, Carlsbad, CA). 
To assess the protein specificity of mAbs, the selected mAbs were tested against PEDV 
structural proteins (S, S1, E, M, and N) transiently expressed in BHK-21 using plasmids with the 
structural proteins (52). The cells transiently expressing the structural proteins were prepared in 
96-well plates, and IIFA was performed in an identical manner as described above. The plates 
were examined under a fluorescence microscope for the presence or absence of virus-specific 
fluorescence staining.  
4.3.10  Virus neutralization (VN) assay  
VN assay was performed as previously described (53) with modifications. In brief, 
samples were first heat inactivated at 56°C for 30 min and then 2-fold serially diluted in 0.01M 
PBS pH 7.4 (Gibco) with 1% BSA from 1:4 to 1:512 in 96-well plates with the final volume of 
100µl per well after dilution. Subsequently, 100 µl of 103 PFU/ml of PEDV was added to each 
well and sample-virus mixtures incubated at 37°C for 1 hr. Then 200 µl of each sample-virus 
mixture was transferred to 96-well plates with Vero cell monolayers, and the plates were 
incubated at 37°C for 1 hr with 5% CO2 supply. After the 1-hr incubation, the cells were washed 
twice with infection media, replenished with the same media (100 µl/well), and incubated further 
for 5 days at 37°C with 5% CO2, monitoring cytopathic effect (CPE). VN titer of each sample 
was determined as the reciprocal of the highest dilution in which 100% blocking of CPE was 
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observed as compared to the negative serum control. Each diluted sample was tested in duplicate 
and four control wells used on each assay, including a positive swine antiserum and rabbit 
hyperimmune serum, a virus control (no antibody), the pre-immunization control serum, and 
negative control (DMEM media only). 
4.3.11  SDS-PAGE and Western immunoblot 
Recognition of the putative PEDV RBD by anti-PEDV swine serum from experimentally 
infected pigs (10) and reactivity of rabbit sera and rat mAbs produced with the RBD protein was 
confirmed by Western immunoblotting. First, the recombinant RBD protein samples and whole 
PEDV antigens were separated on 12% acrylamide gel using SDS-PAGE under reducing 
conditions (50). Each sample was loaded in a 12% polyacrylamide mini-slab gel and 
electrophoresed at 100 Volt (V) for 60 min. Once the electrophoresis was complete, the protein 
was then stained with a Coomassie blue staining solution (40% ethanol, 10% acetic acid and 
0.1% Coomassie brilliant blue) for 2 hr and destained in water. Pictures were captured from the 
stained gel showing visible protein bands using an imaging system (ChemiDoc™ XRS+ System, 
Bio-Rad, Hercules, CA). The molecular weight of the protein was compared with a commercial 
protein ladder with known protein bands (Precision Plus Protein™ Kaleidoscope™ Prestained 
Protein Standards, Bio-Rad, Hercules, CA). Then, the peptides separated on the gel were 
transferred to nitrocellulose membranes for Western immunoblot analysis as previously 
described (52). The unoccupied sites on the membranes were blocked by incubating with 5% 
non-fat dry milk in Tris-buffered saline (TBD), pH 7.4 (ThermoFischer Scientific, Waltham, 
MA) with 0.1% Tween 20 (TBST) for 1 hr at room temperature (RT) and probed with the sera or 
hybridoma culture fluids overnight at 4°C. The membranes were washed three times with TBST 
for 5 min each and incubated with optimally diluted HRP-conjugated goat anti-rat IgG (H+L), 
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anti-rabbit IgG (H+L), and anti-swine IgG (H+L) antibody (Invitrogen, Carlsbad, CA) for 1 hr at 
RT. The membranes were washed again three times with TBST for 5 min each, and antigen-
antibody complexes were visualized by incubating the membrane with TMB substrate 
(Thermofisher scientific, Waltham, MA) for 5 min. The substrate was washed off the membranes 
with deionized water, and images were taken to determine each antibody’s reactivity with the 
putative RBD protein.  
4.3.12  Binding assay 
A protein binding assay as described previously (54, 55) was performed on PEDV 
permissive Vero cells as well as non-permissive cells, BHK-21, and ST cells as control. Briefly, 
cells were plated in 24-well plates with a coverslip in each well to be confluent about 80-90%. 
On the monolayer, 20 µg/well (after several rounds of titration for binding assay) of the 
recombinant PEDV RBD protein (fusion protein with histidine and GFP) was added in both 
media with trypsin and without trypsin. The plate was spun down at 500 x g for 5 min to enhance 
binding and incubated at 37°C for 2 hr. After washing with 0.01M PBS  pH 7.4 (Gibco), cells 
were fixed with 4% paraformaldehyde for 20 min at RT. Cells were washed and incubated with 
antibodies specific for the recombinant RBD protein or PEDV (i.e., rat mAb, rabbit pAb, and 
swine hyperimmune serum) or HIS tag-specific murine mAb at RT for 1 hr. After washing, cells 
were incubated with secondary antibodies (FITC-labeled goat anti-rat, rabbit or swine IgG (H+L) 
(Invitrogen, Carlsbad, CA) or Alexa 594-labeled goat anti-mouse IgG (H+L) (Invitrogen, 
Carlsbad, CA) and incubated at RT for 1 hr. Cell nuclei were stained using a mounting medium 
with ProLong™ Gold Antifade Mountant with DAPI reagent (Invitrogen, Carlsbad, CA). The 




    
4.4  Results 
4.4.1  Identification of a putative RBD of PEDV  
Using T-Coffee program as described in methods, there was a high degree of sequence 
identity in the RBD region among members of the genus Alphacoronavirus suggestive of a 
structure closely related to the RBD of TGEV including the conformation of the receptor-binding 
loops (Fig. 1 and 2) and the viruses were under the same phylogenetic trees (Fig. 1). The 
conserved region within the PEDV S1 protein was selected and subjected to the tertiary structure 
prediction to find a putative RBD of PEDV.  
When the full S1 region amino acid sequence (789 aa) was submitted to I-TASSER, no 
definite structure could be obtained, likely due to the fact that sequence was larger for actual 
structural prediction, and the generated model did not provide a definite structure. However, the 
server selected 10 templates and generated an alignment. Based on the multiple sequence 
alignment, the target protein sequence was narrowed down to 148 aa (position 494-641 of S1 
region) and re-submitted to the server, which generated a predicted structure. The predicted 
structure was used to analyze and visualize the structure of the tentative PEDV RBD (Fig. 2 
upper panels). The different models were viewed in PyMol, and structures were compared with 
TGEV and PRCV RBD in PDB. Among structures generated from I-TASSER, one structure was 
selected based on its similarity to the structure of TGEV and PRCV RBDs (Fig. 2 left upper 
panel). Based on homology modeling, histidine 77 and tyrosine 113 could be the part of RBD of 





    
4.4.2  Expression and characterization of RBD protein 
 The DNA encoding the predicted RBD gene construct was successfully cloned into pCI-
neo vector for expression in BHK-21 cells. The plasmid expressing the gene was transfected into 
BHK-21 cells and the putative RBD protein was recognized by anti-PEDV swine sera using 
fluorescence microscopy, suggesting that the expressed protein may be in its native form as in 
PEDV and be immunogenic to pigs (Fig. 3).  
Recombinant putative PEDV RBD protein fused to an N-terminal super-folding GFP 
along with HIS tag was successfully expressed from HEK293F suspension culture to a high 
amount of protein (160 mg/L). The recombinant putative RBD protein in a fused form was 
approximately 46 kDa and became 25kDa after both tags (GFP and HIS) were cleaved off by 
TEV protease as expected (Fig. 4). The proteins actually appear to have a higher molecular 
weight than expected. This is due to the heavy glycosylation in each protein. The recombinant 
protein (both fused and non-fused forms) was recognized by anti-PEDV swine sera. Similarly, 
PEDV whole virus protein was used as the control, and the viral structural proteins were detected 
as expected (Fig. 5). 
The RBD protein was used to immunize rabbits and determined to be immunogenic as 
rabbit sera collected after the second boost injection reacted with the purified recombinant 
putative RBD protein in a dose-dependent manner as determined by RBD-ELISA (Fig. 6). Anti-
RBD antibody ELISA titers in the rabbit sera remained equivalent at the third and fourth boosts 
(data not shown). The anti-PEDV swine serum showed reactivity with the RBD antigen in 
ELISA similar to the rabbit sera but had a lower titer (Fig. 6). The rabbit sera also reacted with 
PEDV antigens prepared in Vero cells as determined by PEDV-IIFA, suggesting that the 
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recombinant putative PEDV RBD protein maintains the native form of RBD as presented in 
PEDV.  
In addition to antibodies detectable by ELISA and IIFA, the rabbit sera demonstrated 
neutralizing activity against the PEDV isolate (USA/Iowa/18984/2013) as did the anti-PEDV 
swine serum (Fig. 7). The sera collected two weeks after the final boost injection had 1:128 VN 
titer.  
4.4.3  Generation and characterization of RBD-specific monoclonal antibodies  
Twenty RBD-specific mAbs were initially produced and seven of them were selected 
based on their reactivity with both the recombinant RBD protein on ELISA and PEDV on IIFA. 
Among the seven selected mAbs, five of those showed neutralizing activity (1:8 to 1:64 in titer) 
against PEDV. On further expansion, only three of the five hybridoma cell lines were found to 
continuously produce PEDV RBD-specific mAb that neutralized the virus, ranging 1:32-1:64 
VN titer (Table 1). When the five mAbs were tested against PEDV structural proteins (S, S1, E, 
M, and N) transiently expressed in BHK-21 cells using IIFA, all the mAbs reacted with S and S1 
proteins but not with E, M and N proteins, confirming the location of the putative RBD in the S1 
region of PEDV S protein. 
4.4.4  Binding analysis of putative RBD protein. 
In order to assess if the putative RBD protein binds with a surface molecule of permissive 
cells, the recombinant RBD protein tagged with histidine (RBD-HIS) was applied to Vero, ST, 
and BHK-21 cells. Binding of the RBD-HIS protein to the surface of Vero cells, the only cell 
line known to be permissive to PEDV, was apparent but not to that of ST and BHK-21 cells as 
determined by IIFA using anti-RBD mAb and anti-His tag antibody (Fig. 8).  
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4.5  Discussion 
Attachment and entry of PEDV to the host cell is believed to be mediated by S protein of 
the virus since S protein of CoVs plays a crucial role in receptor binding and membrane fusion 
(31). With its critical functions in virus-host interactions, S protein is the major target of humoral 
immune response including neutralizing antibodies (31). Both S1 and S2 regions of PEDV have 
been postulated to contain multiple neutralizing epitopes (23, 24, 28, 29, 32). A recent study has 
demonstrated several neutralizing epitopes in the S1 region (31). Yet, RBD of PEDV within the 
S protein has not been clearly determined. This study was to address such lacking. 
Through bioinformatics, comparative structural biology, and homology modeling for 
protein structure in comparison to alphacoronaviruses with known RBD sequence, a putative 
RBD of PEDV which comprises 148 amino acids, was identified in the C-terminal domain of the 
S1 region of S protein. The recombinant putative RBD protein (glycosylated) produced from that 
gene fragment was recognized by anti-PEDV swine sera, suggesting that the RBD protein retains 
the native form as presented within the virus. As the protein was also recognized by antisera 
from pigs experimentally inoculated with PEDV with deletions in the S protein, also known as 
PEDV S-INDEL strains (data not shown), the identified domain must be present in all PEDV.  
More importantly, the protein showed its binding to the surface of Vero cells (permissive to 
PEDV) but not ST cells (not permissive to PEDV), suggesting that the putative RBD identified 
in the study should be the receptor-binding domain of PEDV or at least a critical portion of 
PEDV RBD. 
In order to determine the model of the tertiary structure of PEDV RBD, we performed 
homology modeling of the predicted RBD and compared with RBDs of TGEV and other 
members of Alphacoronavirus (Fig. 2). Since all of these viruses are in the same genus 
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taxonomically, it is reasonable to assume that PEDV’s receptor binding occurs in a way similar 
to that of other CoVs. Some previous studies have suggested that PEDV uses pAPN (aka, CD13) 
as a functional cellular receptor, which is the same receptor used by TGEV and other 
alphacoronaviruses for cell entry (38, 56). However, recent studies refuted such a postulation by 
demonstrating that pAPN is not a functional cellular receptor of PEDV but enhances virus 
infection through its protease activity (39, 40). In agreement with these recent reports, we 
observed that the putative RBD protein bound to Vero cells which are permissive to PEDV but 
do not possess APN on the surface (41, 57). However, the protein did not bind to ST cells which 
possess APN on the surface but not permissive to PEDV (37) as illustrated in Figure 8. Several 
other cell surface molecules, such as heparin sulfate (58) and sialic acid conjugates (24, 49) have 
been proposed to function as auxiliary cellular receptors although their utility in PEDV infection 
in vitro has varied among PEDV strains. It remains to be determined which cell surface molecule 
corresponds to the putative RBD protein identified in our study. 
The putative PEDV RBD glycosylated protein was immunogenic as it produces the 
protein-specific antibody in rabbits and rats which could be detected by IIFA and ELISA. The 
protein was able to induce a high antibody titer in rabbits only with two doses probably due to 
immunization with good quality and a good amount of the antigen. Production of highly 
immunogenic glycosylated protein in a large quantity may have been attributed to the use of an 
optimized transient human cell expression system as compared to a traditional Baculovirus 
protein expression system. This observation is in agreement with a previous report showing 
better efficiency of glycosylated protein expression in a mammalian system than other eukaryotic 
expression systems such as yeast and insect cells (30). Despite the use of the highly 
immunogenic recombinant protein, no antibody response against the RBD protein was detected 
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in mice even after 4 injections of the protein with adjuvant (data not shown), which led to 
switching the animal source of splenocytes from mice to rats for hybridoma work to generate 
mAbs specific for the RBD protein. The unresponsiveness was not due to any existing immunity 
against coronavirus or something antigenically similar to the RBD protein since mouse sera 
collected before immunization were negative for the virus and the RBD protein. Immune 
tolerance due to the similarity between the RBD protein and one of the host proteins is 
suspected; however, exact reasons remain to be further investigated. 
Both rabbit hyperimmune sera and some of the selected rat mAbs produced in this study 
were able to neutralize PEDV infection to Vero cells which are permissive to PEDV. Such virus 
neutralization may have been due to the presence of a neutralizing epitope(s) in the putative 
RBD protein in its native form since the location of the putative RBD within the S1 unit of 
PEDV (position 494-641) overlaps with one of the predicted neutralizing epitope sites (position 
499-638) by other investigators (28). The observed virus neutralization may also have been 
attributed to the presence of antibodies against viral receptor binding site(s) of the RBD which 
can block virus attachment to the host cell surface directly or indirectly. Several previous studies 
have demonstrated that PEDV S1 protein contains neutralizing epitopes and, as such, is able to 
induce neutralizing antibodies of IgG and IgA isotype which can be passed onto piglets 
providing protective passive immunity (25, 27, 59). However, such neutralizing activity or 
protective immunity may be limited to homologous strains of PEDV according to the previous 
report (27). That limited efficacy would be due to a high degree of genetic and antigenic 
variability in the S1 region among PED viruses (3, 7, 31). Knowing that the putative RBD 
identified in this study is conserved among PED viruses, anti-RBD antibodies may offer a 
benefit to overcome the suboptimal protective immunity by conventional neutralizing antibody 
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against S1 when the RBD protein can be presented to the local immune system adequately. The 
putative PEDV RBD and RBD-specific antibodies produced in the current study may be then 
invaluable to devise improved vaccines for PEDV. 
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Figure 1. Amino acid sequence alignment (top) and phylogenetic relationship (bottom) of the C-
terminal region of the spike S1 proteins of porcine epidemic diarrhea virus (PEDV) and 
Alphacoronaviruses. The C-terminal region (residues 494-641) of the spike (S) protein of the cell 
culture adapted PEDV strains was aligned with the corresponding S protein sequences of 
Alphacoronaviruses described in earlier studies. Protein sequences used are: KF804028.1 
(PEDV) Q0PKZ5 (transmissible gastroenteritis virus, TGEV), Q65984 (canine coronavirus, 
CCoV), P10033 (feline coronavirus, FCoV), P15423 (human coronavirus, HCoV-229), Q6Q1S2 
(human coronavirus, HCoV-NL63), and P15145 (porcine aminopeptidase N, pAPN). The 
sequence alignment was carried out with the T-Coffee program (http://www.ebi.ac.uk/). 
Conserved residues and gaps are indicated in the alignment using the ‘*’ and ‘-’ symbols, 
respectively. Phylogenetic analysis of the S proteins was performed using MEGA 6. Multiple 
sequence alignments from MUSCLE were used to generate a neighbor-joining tree.   
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Figure 2.  Modeling of putative receptor-binding domain (RBD). Models were predicted using I-
TASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) which were downloaded in PDB 
format for evaluation. Images of molecular structures were generated using PyMol (upper left). 
Structural and sequence comparison between the putative porcine epidemic diarrhea virus 
(PEDV) RBD and TGEV RBD is illustrated in the upper right panel. Molprobity 
(http://molprobity.biochem.duke.edu/) was used independently of server scores to evaluate the 
quality of tertiary models (lower panel).  
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Figure 3. Immunofluorescent photomicroscopy of anti-porcine epidemic diarrhea virus (PEDV) 
serum with putative PEDV receptor-binding domain (RBD) protein transiently expressed in 
BHK-21 cells. BHK-21 cells were transfected with pCI-Neo plasmid with PEDV RBD sequence. 
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton-x 100 and 
incubated with PEDV specific hyperimmune serum and MAb against FLAG tag. Goat anti-swine 
IgG labeled with FITC and donkey anti-mouse IgG labeled with AF594 was added and cells 
evaluated under a fluorescent microscope (100 X). Nuclear staining was performed using the 






    
 
 
Figure 4. Recovery of expressed viral receptor-binding protein (RBD) from the culture medium. 
The putative RBD protein of porcine epidemic diarrhea virus (PEDV) was expressed as a fusion 
protein with N-terminal polyhistidine (His) and green fluorescent protein (GFP). The 
recombinant fusion protein was expressed in 293F cells and then TEV digested and purified. The 
purified RBD fragment was visualized with Coomassie brilliant blue staining of the 12% 




    
 
 
Figure 5. Western immunoblot analysis of recombinant putative porcine epidemic diarrhea virus 
(PEDV) receptor-binding domain (RBD) protein. The fused protein and the cleaved pure protein 
were electrophoresed on 12% polyacrylamide gels by SDS-PAGE. Proteins were blotted onto 
nitrocellulose membranes and probed with anti-PEDV swine serum (left) and anti-histidine 
mouse monoclonal antibody (right). PEDV Spike protein corresponds to the topmost band on the 
5th rightmost lane on the left figure.  Blots were developed with a chemiluminescent method. 




    
 
 
Figure 6. Reactivity of sera from rabbits (blue line) immunized with putative porcine epidemic 
diarrhea virus (PEDV) receptor-binding domain (RBD) protein and swine serum (green line) 
from pigs experimentally inoculated with PEDV with the recombinant putative PEDV RBD. 
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Figure 7. Anti-porcine epidemic diarrhea virus (PEDV) neutralizing activity of serum collected 
from a rabbit immunized with the recombinant putative receptor-binding domain (RBD) protein. 
Virus neutralization (VN) assay was done in Vero cells against 103 PFU/ml of PEDV 
(US//Iowa/18984/2013). VN activity was determined at day 5 post inoculation. A convalescent 
swine serum from a pig experimentally inoculated with PEDV and pre-immunized rabbit were 
used as positive control and negative control, respectively. Cell control was not inoculated with 
the virus. Photomicroscopy was performed at 100X magnification. 
  




    
 
Figure 8. Binding of recombinant putative receptor-binding domain (RBD) protein fused with 
His tag to a surface molecule of porcine epidemic diarrhea virus (PEDV)-permissive Vero cells 
(upper panel) and non-permissive BHK-21 cells (bottom panel) as shown by immunofluorescent 
microscopy. Rat monoclonal antibody (mAb) 4B4 that was produced in our laboratory against 
the putative PEDV RBD protein was used to detect the RBD protein. An anti-HIS mAb that 
binds to the HIS tag in the recombinant fusion protein was used as control. The binding was 
visualized with FITC conjugated goat anti-rat antibody (for RBD protein) and Alexa Fluor 494-












    
 
Table 1. Rat monoclonal antibodies produced against a recombinant putative porcine epidemic 
diarrhea virus (PEDV) receptor-binding domain (RBD) protein and their reactivity with the 
recombinant protein on ELISA and PEDV on immunofluorescent assay (IFA) and virus 
neutralizing (VN) activity 
S/N MAbs ID RBD ELISA PEDV IFA VN titer 
1 4B4 3.1* Positive 1:64 
2 5H1 1.16 Positive Negative 
3 8B5 1.48 Positive 1:32 
4 11G11 1.36 Positive 1:64 
5 13E10 1.08 Positive Negative 
6 20G6 1.75 Negative Negative 





    
CHAPTER 5.  GENERAL  CONCLUSIONS 
 
Porcine epidemic diarrhea (PED) remains a significant threat to the US swine industry as 
well as many pig-producing regions around the world. Even though the disease has been around 
in some countries for more than 40 years, there have been frequent re-emergence of epidemic 
PEDVs. This suggests that the virus can evade current control measures including vaccination 
from time to time. Hence, a better understanding of the immunobiology of PEDV including 
pathogenesis and immunity is indispensable for the efficient control of this costly disease.  
The first study in this dissertation characterized clinical and antibody responses and 
serological correlates of protective immunity following infection/reinfection. The appearance of 
clinical diarrhea after PEDV inoculation was similar between naïve nursery and growing pigs. 
Yet older animals appeared to clear the virus faster than younger pigs based on the fecal 
shedding profile. While the disappearance of clinical signs coincided with seroconversion to the 
virus, fecal shedding of the virus continued significantly long after clinical signs ceased, which 
should be taken into consideration for control measure at herds. Unlikely naïve pigs, pigs that 
were previously exposed to PEDV did not become diarrheic but shed the virus in feces when re-
exposed to the homologous strain at 56 days post inoculation (dpi), demonstrating that the 
immunity by prior infection provides clinical protection from subsequent homologous challenge 
at 2 months post inoculation although it is not sterile immunity. Antibody kinetic and profile 
differed between serum and oral fluid (OF). While serum antibodies started to decline steadily 
after 28 dpi, IgA in OF remained at a high level after 35 dpi until re-inoculation, suggesting that 
detection of IgA in OF may provide a better prediction for protective immunity against 
subsequent challenge.  
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The second study of the dissertation was conducted to evaluate if non-intestinal tissues 
play a role in long fecal shedding of virus following infection. The study demonstrated that 
experimental PEDV inoculation resulted in a low-level viremia in early dpi leading to the 
distribution of the virus to a wide range of tissues but did not elucidate strong evidence for virus 
replication in non-intestinal tissues except mesenteric lymph node (MLN). While the 
significance of PEDV replication in MLN for immunity and pathogenesis remains to be further 
studied, the findings from the study strongly suggest that long fecal shedding of PEDV is 
attributed mainly to virus replication in the small intestine. Therefore, effective immune-
mediated control measure for PEDV should focus on how to enhance intestinal mucosal 
immunity against the virus. 
Through bioinformatics and comparative modeling, the third study identified a putative 
receptor-binding domain (RBD) within the S1 region of PEDV S protein which was 148 amino 
acid long and conserved among PED viruses. This identified putative RBD protein induced 
antibodies (rabbit polyclonal antibody and rat monoclonal antibodies) neutralizing PEDV 
infection to Vero cells, the only known permissive cell line, and bound to the surface of Vero 
cells which lacks porcine aminopeptidase N, the known cellular receptor for alphacoronaviruses. 
All these observed characteristics would make this identified putative RBD as a good candidate 
immunogen for the next-generation PEDV vaccine particularly for intestinal mucosal immunity 
if combined with an appropriate delivery system. A set of monoclonal antibodies produced in 
this study can also be a valuable reagent for that endeavor.  
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